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ABSTRACT 
The immune system protects human from cancer through an immunosurveillance 
mechanism. However, the progressive nature of tumor cells to differentiate and the 
complexity of the tumor microenvironment may result in the immunomodulation of immune 
cells. In this thesis, we aim to explore the T cell immunomodulation inside the intricate solid 
tumor microenvironment in patients. 
First, we investigated suppressive regulatory T cells (Tregs) in urinary bladder cancer (UBC). 
Our group previously demonstrated a contradictory finding that a high FOXP3+ tumor 
infiltrating lymphocyte (TIL) number correlates positively to survival. In here, we answered 
that FOXP3+ CD4+ T cells in the tumor were real Tregs which protectively regulated tumor 
invasiveness by suppressing MMP2 expression in tumor-associated macrophages (TAMs) 
and tumor cells. 
Next, we explored the subset of tissue-resident memory CD8+ T (TRM) cells from UBC 
tumor. It is less known whether TRM cells are effective killers of tumor cells. We revealed that 
tumor TRM cells were epigenetically committed to express perforin. Although TRM cells 
expressed exhaustion marker PD-1, they were not terminally exhausted. As a result, we found 
that an increased number of TRM cells in the tumor correlated with a lower tumor stage. 
Furthermore, we looked into the cytotoxic CD8+ T cells in the sentinel nodes (SNs) of UBC 
patients. Surprisingly, we discovered that SN CD8+ T cells displayed a deficiency of their 
cytotoxic constituent perforin, whereas granzyme B was still expressed. Thereafter, we 
revealed that muscle invasive UBC suppressed perforin expression using an ICAM-1/TGFβ2 
– mediated pathway as an immune escape mechanism. 
In the next study, we focused on the effect of standard neoadjuvant chemotherapy (NAC) and 
T cell responses in the SNs. We found that NAC reinforced the anti-tumor T cell activities by 
reducing the exhaustion in CD8+ and CD4+ effector T cells, which consequently increased 
their cytotoxicity and clonal expansion, respectively. Additionally, NAC also reduced the 
frequency and activation of the suppressive Tregs. 
Lastly, as a result of escaping the immune destruction, tumor can grow and metastasize. In 
this study, we revealed that micrometastases in lymph nodes of renal tumors could be reliably 
detected by flow cytometry. This method is more sensitive, objective, time- and cost-effective 
compared to the gold standard histopathological examination. 
In conclusion, T cells are modulated in the solid tumor microenvironment. By understanding 
the molecular and cellular aspects of T cells in this microenvironment, we may unveil new 
strategies for designing cancer immunotherapies in the future. 
  
  
  
POPULAR SCIENCE SUMMARY 
In the human body, the immune system acts as “the army” that fights against “the enemy” 
from outside. The enemies may come in the form of pathogens (viruses, bacteria, parasites, 
and fungi) that cause infections. Over the past decades, it has been widely acknowledged that 
our immune system is also responsible to protect us against the developing tumors.  
The immune system consists of various cell types and each of them has different functions. In 
this thesis, we focus on the immune cells called T cells, which have a crucial role in the 
protection against tumors. In order to be able to destroy the tumors, T cells need to penetrate 
the tumor tissue and stay “behind the enemy lines”. However, the tumor tissue is a very 
complex environment, in which the characters and functions of T cells may be modulated 
inside it. For this reason, we aim to investigate the modulations that happen in T cells in this 
environment. 
We characterized a T cell type called CD8+ T cells, which act as the “assassins” of the tumor 
cells. In order to kill, CD8+ T cells are equipped with weapons, which are called perforin and 
granzymes. We found that in the urinary bladder cancer (UBC) tumor tissue, most of the 
CD8+ T cells were tissue-resident memory T (TRM) cells. These cells were highly-trained to 
kill the tumor cells, even when they were displayed to be exhausted. In addition, we 
discovered that the tumor cells were sneaky and they could avoid the CD8+ T cell killing by 
producing molecules that suppressed the perforin expression. Consequently, CD8+ T cells lost 
their ability to kill, as if they only had guns without the bullets. Moreover, as the result of 
escaping the T cell killing, tumor can grow further and spread (metastasize) to the adjacent 
lymph nodes. In this thesis, we uncovered an alternative method to identify the presence of 
metastatic tumor cells in the lymph nodes using a method called flow cytometry. Flow 
cytometry could detect even a small number of tumor cells, in which standard 
histopathological examination routinely used in the clinic was unable to. 
Furthermore, we examined another type of T cells called the regulatory T cells (Tregs). 
Classically, Tregs are known to suppress the function of activated effector CD8+ and CD4+ T 
cells, so that the over-reaction of T cells will not occur and damage our own normal tissues. 
Accordingly, the suppressive function of Tregs is bad in a T-cell mediated protection against 
the tumors and subsequently, the presence of Tregs in the tumor tissue may promote the 
tumors to grow. Surprisingly, this was not the case, since we found that in the UBC tumors, 
Tregs had a protective effect in regulating the tumor invasiveness. Therefore, it indicates the 
Janus-faced character of Tregs in the tumors. 
Next, we revealed that the standard chemotherapy treatment for UBC could reinforce the 
anti-tumor activities of T cells from the draining lymph nodes of the tumors, which were 
shown to be modulated as described above. We observed that the chemotherapy reduced the 
exhaustion of the killer CD8+ T cells and CD4+ T cells. Consequently, both these cells might 
have better functions to control the tumors. Additionally, the suppressive Tregs were less in 
number and activation after the chemotherapy treatment. This indicates the clinical 
importance of chemotherapy in treatment of cancer patients.  
In conclusion, T cells are modulated inside the tumor tissues. By understanding the 
modulations that happen in T cells in this environment, we may illuminate pathways for 
future cancer immunotherapy development. 
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1 INTRODUCTION 
The term “immunity” has existed for over thousand years. In the ancient Greece, 
Thucydides first mentioned the word immunity in the plague of Athens in 430 B.C. He 
wrote that the people who survived and recovered from the plague did not acquire the 
illness for the second time. The concept of immunity has kept developing since then. In the 
modern world of science, we use the term immunity to define the resistance of the body 
towards infectious diseases. Immunity is further described to consist of molecules, cells, 
tissues, and organs that together constitute the immune system with the ultimate function of 
eradicating pathogens. As the world of science evolves, the role of the immune system goes 
beyond the eradication of infections. Today, we believe that the immune system also 
participates in our defense against the tumors, which is the focus of this thesis.  
There are two main arms of the immune system: the innate and the adaptive immune 
responses. The innate immune response mediates the rapid initial protection against 
infections, whereas the adaptive immune response is activated later during the course of 
infections. These two responses have a complementary action to each other. The initial 
induction of the innate immune response is mediated by the germline-encoded pattern 
recognition receptors (PRRs) upon microbial infection or tissue damage. PRRs recognize 
pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs). This process will in turn activate the acute inflammatory reaction for the purpose 
of microbial elimination and tissue repair [1]. Additionally, the innate immune response has 
a role in activating the adaptive immune response, which consists of T and B cells. In this 
thesis, we set our focus on T cells. The innate antigen presenting cells (APCs) have the 
capacity to present antigenic peptides to T cells via T cell receptor (TCR) and major 
histocompatibility complex (MHC) [2]. The process of adaptive immune response 
activation takes longer time compared to the innate immune activation. However, the 
adaptive immune response provides a specific and long-term immunity, which is essential 
in the immune protection against cancer.  
Cancer is a major global health burden. In 2013, the global cancer burden was registered to 
display 14.9 million incident cases with approximately 8.2 million deaths [3]. This number 
is projected to increase into 22.2 million incident cases by the year 2030 [4], posing for a 
serious threat. As the entire field of cancer research develops, it has been demonstrated that 
the immune system has a significant role in the cancer regression or progression [5]. This 
complex interplay between the tumor and immune system, especially T cells, within the 
intricate tumor microenvironment is something that needs further exploration.  
  
 2 
1.1 T CELL ACTIVATION 
1.1.1 T cell development 
The development of T cells starts when the hematopoietic stem cells (HSCs) are constantly 
recruited from the bone marrow into the thymus. During their journey towards the thymus, 
HSCs become more and more restricted in their fate, and give rise to the earliest thymic-
seeding progenitor (TSP) (Figure 1). As the TSP enters the thymus, it will progress into the 
early thymic progenitor (ETP), which is a CD4-CD8- double negative (DN) thymocyte. The 
thymus provides the microenvironment for the DN thymocytes in order to develop into a T 
cell lineage. DN thymocytes are comprised of four differentiation stages (DN1 to DN4), 
based on their expression of CD25 and CD44 [6].  
During the development processes, there are three important checkpoints for the thymocyte 
maturation into becoming T cells. The first critical checkpoint takes place in the phase of 
DN1 thymocyte, where the Notch signaling pathway plays an important role by inhibiting 
the multiple cell fate potential of a thymocyte (myeloid cell, natural killer/NK cell, and 
dendritic cell/DC), leading the development towards the T cell lineage [7] (Figure 1).  
 
 
 
 
 
 
The next checkpoint is the β selection of the TCR. This occurs during the transition 
between DN3a to DN3b thymocytes, in which the rearrangement of TCR genes start, which 
takes place in the subcapsular zone of the thymus (Figure 1). However, before the 
formation of the αβ-TCR, the developing thymocytes express the pre-TCR comprising of 
the rearranged TCR-β chain and the pre-TCR-α chain, due to the later rearrangement of the 
Figure 1. T cell development in the thymus. The development of T cells starts when the TSP deriving 
from HSC enters the thymus and differentiates into CD4-CD8- DN thymocytes. In the thymus, there are 
three important checkpoints that shape the T cell development: Notch signal, β selection, and positive 
and negative selections. The locations within the thymus where each process occurs are shown. DN: 
double negative, DP: double positive, HSC: hematopoietic stem cell, SP: single positive, TSP: thymic-
seeding progenitor.  
Adapted from Koch U, et al. Annu. Rev. Cell Dev. Biol. 2011 
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TCR-α gene. The TCR-β chain, in the absence of the TCR-α chain, is capable to induce the 
expression of two co-receptors CD4 and CD8, yielding a double positive (DP) thymocyte 
[8]. After this process, TCR-α recombination is initiated and a functional TCR-αβ complex 
is formed and expressed by the thymocytes.  
At the last checkpoint, the DP thymocytes will undergo a positive selection based on their 
specificity and affinity to self-peptide-MHC complexes presented by the cortical thymic 
epithelial cells (cTECs). The positively selected cells will then commit into either single 
positive (SP) CD8 cells or CD4 cells, based on their recognition to the MHC class I or 
MHC class II, respectively (Figure 1). The next process is the negative selection of the SP 
cells which occurs in the thymic medulla (Figure 1). SP cells with a high affinity towards 
self-antigens presented by the medullary thymic epithelial cells (mTECs) will be 
eliminated, in order to reduce the chance of releasing auto-reactive T cells into the 
periphery [9]. Following this chain of events, CD8+ and CD4+ T cells start leaving the 
thymus as naïve T cells. The naïve T cells will circulate to the secondary lymphoid organs 
and are ready to be presented to the peptide antigens by APCs. 
1.1.2 T cell receptor activation 
In the secondary lymphoid organs, naïve T cells will be activated following the presentation 
of peptide antigens by the APCs. This presentation is mediated by MHC molecules 
expressed on APCs, which present the peptides to the αβ-TCR on T cells. The MHC 
molecules are sub-classified into MHC class I and MHC class II, which are recognized by 
the CD8+ and CD4+ T cells, respectively [10]. Following antigen recognition by T cells, 
biochemical changes will take place in the cytoplasmic portion of the CD3 complex, in 
which the phosphorylation of the immunoreceptor tyrosine-based activation motifs 
(ITAMs) expressed by protein members of the CD3 complex occurs [11]. This event will 
lead to the downstream intracellular signal transduction. 
1.1.3 Co-stimulation and co-inhibition 
Nevertheless, activation through the TCR alone (signal 1) will result in an anergic state of 
unresponsiveness of the T cells. Therefore, an additional co-stimulatory signal (signal 2) is 
needed to induce a potent activation of the T cells [12]. There are several co-stimulatory 
molecules that have been identified. One of them is CD28. Upon TCR stimulation, CD28 
will bind to its ligands CD80 or CD86, expressed on APCs, resulting in induction of the 
downstream PI3K signaling pathway [13]. Additionally, multiple co-stimulatory receptors 
have been described participating in T cell activation, such as ICOS, OX40, and 4-1BB [14, 
15].  
Besides the existence of co-stimulation to elicit a potent T cell activation, co-inhibitory 
signals are also needed to regulate the immune response. The co-inhibition acts as a 
peripheral tolerance mechanism in order to prevent an exaggerated T cell response that 
potentially could lead to harm and even autoimmunity. Two co-inhibitory molecules widely 
described are the cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 
 4 
(PD-1). CTLA-4 acts by setting up a competitive binding towards the co-stimulatory CD28 
ligands, CD80 and CD86 on APCs [16]. As for PD-1, upon engagement to programmed 
death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2), Src homology region 2 
domain-containing phosphatase-1 and 2 (SHP-1 and SHP-2) will be recruited into the 
immunoreceptor tyrosine-based switch motif (ITSM) in the cytoplasmic tail of PD-1 [17]. 
Consequently, this event will lead to a negative regulation of the T cell activation. 
1.1.4 T cell lineage differentiation 
Since naïve T cells are activated via the recognition of specific peptide antigens mediated 
by TCR-MHC complexes and co-stimulatory signals, the presence of polarizing cytokines 
secreted by the APCs (signal 3) will determine the lineage differentiation of CD8+ and 
CD4+ T cells [18]. The classically established T cell subsets are CD8+ T cytotoxic 1 (Tc1) / 
CD4+ T helper 1 (Th1) and CD8+ T cytotoxic 2 (Tc2) / CD4+ T helper 2 (Th2) [19, 20]. 
Priming by IL-12 cytokine will polarize naïve T cells into becoming Tc1/Th1 cells, 
whereas IL-4-priming will result in Tc2/Th2 cells [21] (Figure 2).  
 
 
 
 
 
Figure 2. The lineage differentiation of T cells. Once the naïve CD8+ and CD4+ T cells are activated 
via TCR-peptide-MHC complex and co-stimulatory signals, the presence of priming cytokines will 
polarize the T cells into a specific lineage. Consequently, the differentiated T cells will express lineage-
specific transcription factors and produce their respective cytokines. CD8+ T cells will develop into Tc 
subsets, whereas CD4+ T cells will develop into Th subsets. IFNγ: interferon-γ, IL: interleukin, iTregs: 
induced regulatory T cells, STAT: signal transducer and activator of transcription, Tc: T cytotoxic cells, 
TGF-β: transforming growth factor-β, Th: T helper cells, TNF-α: tumor necrosis factor-α. 
 
  5 
Following the cytokine stimulation, the expression of lineage-specific transcription factors 
will be promoted. Expression of T-bet will promote the development of Tc1/Th1 cells and 
GATA3 for the development of Tc2/Th2 cells (Figure 2). Moreover, the downstream 
signaling molecules such as signal transducer and activator of transcriptions (STATs) will 
be differentially induced in distinct T cells subsets. In addition, the T cell subsets can be 
functionally distinguished by their respective cytokine production. The signature cytokines 
for Tc1/Th1 cells are interferon-γ (IFNγ) and tumor necrosis factor-α (TNF-α), whereas 
Tc2/Th2 cells produce IL-4, IL-5, and IL-13 [22, 23] (Figure 2).  
As the study of T cell fate progresses, additional subsets of CD8+ and CD4+ T cells have 
been identified. These cells are the Tc17/Th17 cells, which express the transcription factor 
RORγt and the CD8+ or CD4+ regulatory T cells (Tregs), which are marked by their 
lineage-specific transcription factor FOXP3 [22, 23] (Figure 2).  
Although having a specific distinct fate, CD8+ and CD4+ T cells have been demonstrated to 
display lineage plasticity. In CD4+ T helper cells, for instance, IFNγ production can be 
exerted from Th2, Th17, or Tregs by stimulation using IL-12 [24, 25]. Similarly, for CD8+ 
T cells, Tc2 and Tc17 can additionally produce IFNγ, with maintained expression of their 
signature cytokines [26, 27]. Hence, in the presence of proper polarizing conditions, 
differentiated T cells can be reprogrammed into other cell lineages, implying their situation-
dependent plasticity.   
 
1.2 EFFECTOR FUNCTIONS OF T CELLS 
1.2.1 CD8+ T cells   
Since CD8+ T cells recognize the target cells directly via MHC class I-peptide complexes, 
they can immediately kill the target cells using their effector cytotoxic constituents, perforin 
and granzymes. Upon antigenic recognition by the CD8+ cytotoxic T cells (Tc1), additional 
molecules take charge in the formation of the immunological synapse (IS). One of the 
major molecules responsible in the IS formation is the lymphocyte function-associated 
antigen 1 (LFA-1) integrin, expressed by CD8+ T cells, which will bind to its ligand 
intercellular adhesion molecule 1 (ICAM-1), expressed on the surface of the target cells. 
These two molecules firmly hold the two cells together, forming the IS, and thus optimizing 
the activation of the T cells. The IS formation has a lifespan of 20-30 minutes [28]. 
Following this event, microtubule organizing center (MTOC) will polarize towards the IS 
and the lytic granules containing the cytotoxic constituents will move towards the IS along 
the microtubules. Accordingly, the accumulation of the lytic granules below the plasma 
membrane occurs [29]. Next, the gap in the cortical actin opens below the central 
supramolecular activation complex (cSMAC), which will allow the cytotoxic constituents 
to be secreted into the IS [30]. 
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Once the cytotoxic constituents are degranulated from the CD8+ T cells, perforin first starts to 
bind to the surface of the target cells to form pores [31] (Figure 3). These pores will allow 
granzymes to enter the cytosol of the target cells and induce apoptosis. Granzyme B, the most 
prominent class of granzymes, promotes apoptosis in two pathways: caspases activation or 
BH3 interacting-domain death agonist (BID)-dependent mitochondrial permeabilization [32, 
33]. Moreover, another important class of granzymes, granzyme A, promotes cell death by 
several mechanisms, such as mitochondrial trans-membrane potential reduction and reactive 
oxygen species (ROS) generation [34].  
 
 
 
 
 
The importance of perforin in the cancer immunity is marked by the increased susceptibility 
to cancer in the people with perforin gene (PRF1) mutations [35]. Additionally, perforin-
knockout mice have an increased frequency of spontaneously developed tumors [36]. This 
implies that granzyme-mediated killing of tumor cells by CD8+ T cells is secondarily 
affected, since non-functional perforin cannot facilitate the obligated intracellular delivery of 
granzymes. Conversely, it was demonstrated that mice which are lack of individual 
granzymes remain cancer free [32], further supporting the importance of perforin for CD8+ T 
cell-mediated tumor cell killing.   
1.2.2 CD4+ T helper cells 
CD4+ T helper cells play a crucial role in helping in the maintenance of other immune cells, 
such as macrophages, B cells, and CD8+ T cells [37]. There have been several studies 
within the field in investigating the support given by the CD4+ T helper cells to CD8+ T 
cells. Classically, CD4+ T helper cells provide IL-2 for CD8+ T cells in order to maintain 
their clonal expansion [38]. In addition, CD4+ T helper cells promote the maintenance of a 
CD8+ T cell fraction as long-term memory cells, which ensures the availability of effector 
CD8+ T cells upon recall activation [37].  
Figure 3. The cytotoxic activity of CD8+ T cells. Upon the encounter of a CD8+ T cell to the tumor cell, 
the lytic granules containing the cytotoxic constituents inside the CD8+ T cell will move towards the 
immunological synapse and secrete perforin and granzymes. Perforin will form pores that allow 
granzymes to enter the cytosol of the tumor cells and induce cell death. 
  7 
Additionally, CD4+ T helper cells have been described to regulate CD8+ T cell responses 
via the CD40/CD40L pathway. CD40, expressed by the APCs, will be stimulated by 
CD40L that is expressed by the antigen-stimulated CD4+ T helper cells. The net result is 
potent activation of the APCs, demonstrated by the increased expression of MHCs and co-
stimulatory receptors, enhanced cytokine production, and elevated expression of 
chemokines. The activated APCs will in turn support the maintenance of the CD8+ T cell 
response [39]. Moreover, it was demonstrated that the delivery of CD4+ T helper cells is 
facilitated by a CD27/CD70 co-stimulatory pathway, expressed by CD8+ T cells and APCs 
[40]. Hence, the interaction among CD4+ T helper cells, APCs, and CD8+ T cells is well-
preserved. 
Furthermore, in the tumor model, the presence of CD4+ T helper cells results in a lower 
expression of co-inhibitory receptors, such as PD-1, B- and T-lymphocyte-associated 
protein (BTLA), and lymphocyte activation gene 3 protein (LAG3) in CD8+ T cells. 
Consequently, by support from CD4+ T helper cells, CD8+ T cells will have better effector 
responses and anti-tumor activities, as well as an improved migratory capacity [40].  
1.2.3 Regulatory T cells 
T cell activation via TCR-peptide-MHC complex can lead to the generation of pathogenic 
auto-reactive T cells. Therefore, the mechanisms of peripheral tolerance through the co-
inhibitory receptors CTLA-4 and PD-1 are needed to avoid such auto-reactivity, as 
described above. However, these peripheral tolerance mechanisms may not be sufficient in 
controlling the activated T cell response. Hence, a specific immune cell subset to regulate 
the T cell activity has evolved.  
The groundbreaking discovery of a CD4+ T cell subset with a high expression of IL-2 
receptor α-chain (CD25) further supports this notion [41]. This cell subset is called 
regulatory T cells (Tregs). Natural Tregs (nTregs) are formed in the thymus and they 
possess suppressive functions [41]. Furthermore, FOXP3 has been identified as the 
transcription factor which is stably expressed by the Tregs and it is needed to maintain the 
functional suppressive phenotypes of Tregs by affecting the transcriptional programming 
[42]. The importance of Tregs has clinically been demonstrated since patients with 
mutations of FOXP3 gene (IPEX syndrome) are lack of Tregs and suffer from severe 
autoimmunity and unregulated T cell proliferation [43].  
Several effector mechanisms of Treg functions in suppressing the effector T cell activity 
have been discovered. One of them is by highly expressing CD25 on Tregs, resulting in IL-
2 overconsumption. This leads to poor IL-2 stimulation of effector T cells which is needed 
for proliferation [44]. Moreover, Tregs express the co-inhibitory receptor CTLA-4 which 
inhibits the effector T cell activity [45]. CTLA-4 possesses a higher affinity than co-
stimulatory receptor CD28 towards CD80 or CD86 expressed on the APCs, resulting in the 
inhibition of CD28 – CD80/CD86 ligation. Consequently, the co-inhibitory signal 
activation will deliver a negative regulatory signal to the APCs [46]. Additionally, PD-1 
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expression on Tregs is demonstrated to contribute in suppressing the function of CD8+ T 
cells [47].   
Moreover, other molecules such as CD39 and CD73 are expressed by the Tregs and 
contribute to the Treg-mediated suppression of the effector T cells. CD39 and CD73 can 
catalyze the generation of adenosine from the adenosine triphosphate (ATP). 
Correspondingly, the engagement of adenosine to its receptor on the effector T cells will 
induce intracellular cyclic adenosine monophosphate (cAMP) expression, resulting in 
limited T cell proliferation [48]. 
Aside from the trans-membrane molecule expression, Tregs also secrete cytokines such as 
IL-10, IL-35, and transforming growth factor-β (TGF-β). These cytokines also inhibit local 
effector T cell immune response [49]. For instance, TGF-β has been displayed to suppress 
CD4+ Th1 cell response [50]. Other secreted proteins like granzyme B is also demonstrated 
to contribute in the Treg-mediated suppressive activity. Granzyme B will induce cytolysis 
by promoting apoptosis of the effector T cells [51].  
To summarize, Tregs as part of the peripheral tolerance, have a vital role in avoiding T cell-
induced autoimmunity. Several mechanisms are utilized by Tregs in order to suppress 
effector T cell immune response, which may be used under different conditions.  
 
1.3 T CELL MEMORY  
1.3.1 The memory formation 
The classical fate of a T cell starts when a mature naïve T cell derived from the thymus met 
its cognate antigen in the secondary lymphoid organs. This event will result in the 
differentiation and clonal expansion of T cells with effector functions as explained above. 
However, effector T cells are short-lived and following elimination of the antigens, most of 
them will die by apoptosis. This process is called the contraction phase. Correspondingly, a 
small fraction (~5-10%) of the remaining T cells will survive and differentiate into memory 
T cells with the capacity to be present for a long-term within the body [52, 53]. 
Memory T cells have a signature surface marker expression of KLRG1low, IL-7Rα 
(CD127)hi, CXCR3hi, and CD62Lhi [52]. It was recently demonstrated that upon contraction 
phase, KLRG1+ effector CD8+ T cells will downregulate their KLRG1 expression in a 
Bach2-dependent fashion, which allows them to differentiate into different memory subsets 
[54]. Additionally, several sets of transcription factors are described to regulate the memory 
formation of T cells in a competing manner. Transcription factors such as EOMES, BCL-6, 
ID3, and STAT3 maintain the memory properties of T cells instead of their effector 
phenotypes. Conversely, the opposing transcription factors like T-bet, BLIPM1, ID2, and 
STAT4 counter-regulate T cells to promote effector profiles [55-57].  
Furthermore, cellular metabolism is reported to regulate the memory formation of T cells 
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from the effector state. Following antigenic clearance, effector T cells, dependent on 
anabolic metabolism by glycolysis as the energy source, will switch into catabolic 
metabolism involving the fatty acid oxidation and the mitochondrial oxidative 
phosphorylation, resulting in a memory cell formation [58]. Moreover, the pathways 
involved in governing the effector to memory state transition are related to the effector-
promoting phosphatidylinositol 3-kinase – AKT – mammalian target of rapamycin (PI3K-
AKT-mTOR) and AMP-activated protein kinase (AMPK) pathways. During the memory 
formation, AMPK will inhibit mTOR activity and thus promote the fatty acid oxidation, 
needed in the memory T cell formation [58, 59]. Correspondingly, mTOR inhibition may 
regulate the translational programming of the ribosomal proteins, which is observed to be 
suppressed in the terminal effector cells, just before the contraction phase [60].  
An additional mechanism involved in the T cell memory formation was further identified. 
S-2-hydroxyglutarate (S-2HG) is demonstrated to be produced by CD8+ T cells following 
TCR activation. S-2HG induces transcriptional signature similarly found in the memory 
CD8+ T cells, such as upregulation of Cd62l, Cd127, Bcl6, and Eomes, as well as 
downregulation of Prdm1 (encoding Blimp1), which promotes the memory T cell 
formation [61].  
The outstanding feature of the memory T cells is their long-term persistence within the 
body. Accordingly, continuous maintenance to preserve their lifespan is crucial. It was 
demonstrated that the maintenance of memory CD8+ T cells is antigen-independent and 
cytokine-dependent through continuous IL-15 and IL-7 stimulation [62]. IL-15 works by 
sustaining the basal proliferation, while IL-7 maintains cell survival [63]. As for the 
memory CD4+ T cells, their maintenance seems to be also supported by IL-15 [64]. 
However, it is still unclear whether the persistence of antigen is needed in preserving 
memory CD4+ T cells.  
1.3.2 The memory subsets 
The most vital feature of memory T cells is the ability to respond more rapidly and 
effectively upon re-exposure to antigens. Correspondingly, the location of memory T cells 
is crucial for a rapid and effective immunosurveillance. Classically, two memory T cell 
subsets have been identified: central memory T (TCM) cells and effector memory T (TEM) 
cells. TCM cells are CD45RA-CCR7+CD62L+ and they traffic to the secondary lymphoid 
organs, whereas TEM cells are CD45RA-CCR7-CD62L- and they recirculate through non-
lymphoid tissues and blood [65] (Figure 4). Accordingly, due to the possibility of 
recirculation, both TCM and TEM cells can be found in the peripheral blood [66]. These two 
cell subsets have some phenotypical distinctions. TCM cells own a better proliferative 
capacity upon activation than TEM cells, but TEM cells possess greater effector activities, i.e. 
cytokine production by CD4+ TEM cells and cytotoxic molecule expression by CD8+ TEM 
cells [67] (Figure 4).  
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Furthermore, some TEM cells gain CD45RA expression, which are then defined as TEMRA 
cells. TEMRA cells are terminally differentiated and the upregulation of CD45RA occurs 
after homeostatic cytokine stimulation on memory T cells instead of antigen stimulation 
[68].  CD8+ TEMRA cells are demonstrated to express the highest amount of cytotoxic 
molecules like perforin [69], and they reside in the blood, spleen, bone marrow, and lungs 
[70] (Figure 4). However, TEMRA cells display a low proliferative capacity and they are 
short-lived [68, 69]. 
 
 
 
 
 
Emerging evidence in this field further answers the question of whether TEM cells would 
keep recirculating for surveillance or that they remain in the non-lymphoid tissues. This 
question was answered by the work done using infection models, which led to the discovery 
of tissue-resident memory T (TRM) cells [71, 72]. TRM cells, which are well-described in 
CD8+ T cell compartment, have a specific feature of not recirculating in the peripheral 
blood and instead they localize in the non-lymphoid tissues, such as intestines, skin, brain, 
Figure 4. The T cell memory subsets. Following contraction phase, the remaining effector T cells 
differentiate into memory T cells with different subsets. Each memory subset has different phenotypes, 
localizations, and functions. TCM: central memory T cells, TEM: effector memory T cells, TEMRA: effector 
memory T cells with CD45RA upregulation, TRM: tissue-resident memory T cells.  
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lungs, and female reproductive tract [73]. The differentiation, maintenance, and residency 
of TRM cells are controlled by Runx3 [74]. These cells have two key surface markers, which 
are CD69 and CD103 [75] (Figure 4). CD69 causes T cell retention in the tissue due to its 
antagonistic effect towards sphingosine-1-phosphate receptor 1 (S1PR1) that mediates 
egress from tissues [76]. Meanwhile, CD103 that is an αE integrin, will pair to the β7 
integrin and bind to E-cadherin expressed on epithelial cells, contributing to their 
persistence in the non-lymphoid tissues [63, 73, 77]. In addition, TRM cells in the skin are 
characterized by their expression of CD49a [78]. 
Accordingly, TRM cells harbor effector-like properties, they are localized in the non-
lymphoid tissues, and they provide a bona fide immediate protection and elimination 
following secondary antigenic exposure [63] (Figure 4). Moreover, TRM cells in the non-
lymphoid tissues are recently reported to give rise to the TRM cells in the draining lymph 
nodes following secondary antigenic challenge. This indicates the possibility of 
immunosurveillance by the TRM cells in the regional lymph nodes [79].  
 
1.4 EPIGENETIC REGULATION OF THE T CELL PHENOTYPE 
1.4.1 Epigenetics – the concept 
The term „epigenetics‟ is defined as the inherited pattern of gene expression without the 
changes in the DNA sequence. Epigenetics act by stabilizing the gene expression 
programming, which thus results in the determination of a cell identity [80]. The two 
extensively studied mechanisms in the field of epigenetics are the DNA methylation and 
histone modifications.  
DNA methylation occurs in the cytosine residue (5-methylcytosine) of a cytosine-
phosphate-guanine (CpG) dinucleotide and most studies concentrate on the methylation 
profile of the CpG-rich regions (CpG islands) [81]. Commonly, CpG islands are found in 
the promoter regions of genes, however they can also be located in the exons [81]. DNA 
methylation allows the binding of the methyl-CpG-binding domain (MBD) protein to the 
methylated CpG, which makes it impossible for transcription factors to bind to the 
methylated CpG. Consequently, this event results in a transcriptional repression [82]. 
Another epigenetic regulation occurs in the form of histone modifications. As widely 
known, DNA is packed into nucleosomes with eight histone components (two copies of 
H2A, H2B, H3, and H4). Generally, the acetylation of the histones promotes transcription, 
whereas methylation may have a positive or negative effects on transcription [83]. 
As mentioned above, T cells have the capacity to differentiate into different effector and 
memory subsets following naïve T cell activation. This phenotypical plasticity of T cells 
which have an identical underlying genome may be partly accounted by epigenetics. In T 
cell differentiation, epigenetics regulate a cell lineage-specific transcriptional program 
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leading to different cell-lineage-specific phenotypes [84]. Therefore, epigenetic regulation 
is responsible to maintain a heritable cell lineage commitment.  
1.4.2 Epigenetic regulation in CD8+ T cells 
Upon external stimulation on CD8+ T cells that promotes cell differentiation, epigenetic 
regulation in terms of DNA methylation and histone modifications was demonstrated to 
serve the signature transcriptional programing of each cell lineage [85]. A study using a 
single-cell RNA sequencing approach revealed that after CD8+ T cells are antigen-
stimulated, the changes of epigenetic and transcriptional regulation within the cells occur 
since the first cell division, resulting in distinct gene profiles between effector and memory 
cell subsets [86].  Accordingly, DNA methylation profile of signature genes differs among 
differentiated memory CD8+ T cell subsets, such as stem cell memory T (TSCM) cells, TCM 
cells, and TEM cells.  
Notably, the DNA methylation status of the signature loci remains unchanged even after 
three consecutive rounds of cell division using homeostatic cytokines IL-7 and IL-15 
stimulation [87]. For instance, it was seen in the effector-associated genes PRF1 and IFNG 
that there is no change in the methylation pattern of undivided and divided cells [87], 
marking a crucial role of epigenetics in maintaining effector cell lineage commitment. In 
contrast, selected genes responsible for homing (CCR7) and self-renewal regulation (TCF7) 
can be reprogrammed in long-lived TSCM and TCM cells following homeostatic ex vivo 
stimulation [87]. This indicates that the epigenetic regulation may be flexible on selected 
genes in order to rapidly differentiate from memory into effector cells.  
Furthermore, it was demonstrated that during differentiation, CD8+ T cells have highly 
dynamic [88] and distinct enhancer repertoires as determined by the intensity of H3K4me1 
signal [89]. Correspondingly, these different sets of enhancers regulate the expression of 
lineage-specific signature genes [89]. In addition, epigenetic modification of a lineage-
specific enhancer will lead to a lineage-specific gene transcription [84]. Therefore, it 
indicates that the epigenetic regulation of the lineage-specific enhancers is crucial for CD8+ 
T cell subset generation and maintenance.   
1.4.3 Epigenetic regulation in regulatory T cells 
Major discovery in the field has appointed FOXP3 as the marker for regulatory T cells 
(Tregs) [90]. However, since conventional CD4+ T cells also transiently express FOXP3 
upon activation [91], further quest was to find an answer whether FOXP3 served as a 
specific lineage marker for human Tregs. To this end, investigation of the epigenetic 
regulation by means of DNA methylation in the regulatory regions of the FOXP3 gene may 
aid us in identifying truly committed Tregs. 
Studies over the years have identified specific DNA methylation patterns in the FOXP3 
gene that reflects a specific Treg lineage. Our group has discovered that hypomethylation in 
the CpG position -77 located in the promoter, to be specific for a stable FOXP3 expression 
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in Tregs [92]. This methylation pattern is not observed in the conventional T cells, even 
after activation [92].  
In addition, investigation done by other groups demonstrated that demethylation of CpGs 
located in the conserved non-coding sequence (CNS) of the FOXP3 gene is specific for 
Tregs and is not displayed in the activated conventional T cells [93, 94]. 
In conclusion, epigenetic modifications of the FOXP3 gene help us in identifying the 
committed Tregs with stable phenotypes. Treg identity is important to be apprehended, 
especially in the arena of cancer immunology research where tumor Treg infiltration may 
lead to either positive or negative prognosis [95]. 
 
1.5 THE TUMOR MODELS 
In this thesis, we used two human urological tumor models which derived from urinary 
bladder cancer and renal cancer. The disease background of each tumor is further explained 
below. 
1.5.1 Urinary bladder cancer 
Urinary bladder cancer (UBC) is the fourth most common cancer in men and the ninth in 
women in the western world [96], with 429.000 estimated new cases worldwide [97]. Some 
risk factors have been identified for UBC, including tobacco smoking and occupational 
irritants [98]. In the majority of the cases, UBC shows the histopathological feature of 
urothelial type (90%) [99]. Moreover, about 25% of the cases displays muscle invasiveness, 
which contributes to the higher probability of developing metastasis and worse survival 
outcome [96].  
The non-muscle invasive form of the UBC (75% of the cases) is diagnosed by transurethral 
resection of the bladder (TUR-B), which aims to secure the diagnosis and remove the visible 
lesion [100]. Adjuvant treatment following TUR-B, such as intravesical chemotherapy or 
intravesical Baccilus Calmette Guérin (BCG) treatments may prevent recurrences of the non-
muscle invasive UBC [100]. The BCG treatment acts by inducing the anti-tumor immune 
activation resulting in tumor regression [101]. 
For the muscle invasive UBC, TUR-B is also performed for the diagnostic and therapeutic 
purposes. Patients proven to have a muscle invasive UBC by the histopathological 
examination, will be managed by radical cystectomy [102]. In addition, for fit patients, 
cisplatin-based chemotherapy prior to surgery (neoadjuvant chemotherapy) is the standard 
treatment for the muscle invasive UBC [98, 102]. The neoadjuvant chemotherapy has been 
shown to reduce micrometastasis and improve patient survival [102]. Moreover, the 
advantages of providing neoadjuvant chemotherapy prior to radical cystectomy include: the 
delivery is done when the micrometastatic disease burden is still low, potential in vivo 
chemo-sensitivity, better tolerability of chemotherapy regimen prior to cystectomy compared 
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to after it, and favorable histopathological examination with negative lymph nodes and 
surgical margins can be determined following radical cystectomy operation [103]. 
Consequently, the inclusion of neoadjuvant chemotherapy in the treatment regimen will give 
5-8% overall survival advantage to the patients [104-106], in which only 50% of the 5-year 
survival rate is displayed when radical cystectomy alone was provided [107].  
Furthermore, cancer immunotherapy involving immune checkpoint blockade has been 
demonstrated to provide promising results for UBC. Atezolizumab, which is a PD-L1 
inhibitor, is now approved for UBC treatment [108]. Additionally, more studies investigating 
other targets for immune checkpoint blockade are currently ongoing in clinical trials. 
1.5.2 Renal cancer 
Renal cancer or renal cell carcinoma (RCC) is one of the most common cancers with 338.000 
new cases worldwide in 2012 [109]. The incidence of RCC increases with age and is more 
common in males [109]. Some identified risk factors include high body weight, hypertension, 
and cigarette smoking [110]. This cancer has a broad spectrum of histopathological entities, 
in which clear cell type is named as the most common (75% of incidence), followed by 
papillary type (10%) and chromophobe type (5%) [111].  
The prognosis of RCC can be unpredictable. It was demonstrated that 4.2-7.1% of patients 
presented with tumor mass ≤4 cm may have a metastasis. On the contrary, 40% of the 
patients with lymph node metastasis are alive after five years of being diagnosed with RCC 
[112]. This emphasizes that proper diagnosis is critical, especially in establishing the presence 
of metastasis in RCC. Accordingly, cytological biomarker such as carbonic anhydrase IX 
(CA9) has been studied and considered as a tool in predicting the diagnosis and prognosis of 
clear cell RCC [113]. This further aids in solving the intricate problem of patient prognosis 
prediction in RCC. 
The gold standard diagnostic procedure for RCC is the histopathological examination of the 
tumor biopsy. This tool will determine the next treatment modalities for the patients, which 
may involve partial or radical nephrectomy [114]. Moreover, as the era of cancer 
immunotherapy progresses in the past decades, RCC has also been treated using this 
treatment modality. Cytokines such as IFN-α and IL-2 have been used as RCC treatments 
[115], however they give a substantial toxicity. Furthermore, immune checkpoint blockade 
agents against PD-1, PD-L1, or CTLA-4 are currently investigated for their benefit and 
patient tolerability for treating RCC [110]. 
 
1.6 TUMOR MICROENVIRONMENT 
The field of research in tumor microenvironment was pioneered by Stephen Paget over a 
hundred years ago. Based on his observation in breast cancer metastasis, Paget proposed the 
concept of „seed and soil‟, in which tumor cells are like seed of plants that are carried around 
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until they find the favorable soil (organs) to live and grow [116]. This hypothesis underlies an 
understanding of an existing relationship between tumor cells and the microenvironment that 
supports the tumor growth.  
As the research expands, the tumor microenvironment composition is discovered to be 
beyond the earlier proposed concept. Tumor microenvironment is revealed to be consisting of 
the tumor cells, residing or recruited cells, extracellular matrix (ECM), and environmental 
conditions like hypoxia, acidosis, and increased interstitial pressure. Correspondingly, all 
these components will have active interactions with the tumor cells that may support or 
oppose the tumor growth [117].  
Mounting evidence has demonstrated the impact of ECM remodeling in the tumor 
microenvironment to the tumor invasion and metastasis. The remodeling of ECM is 
correlated with the production of fibronectin, lysyl oxidase, and type I collagen which are 
associated with the transition from cellular dormancy in tumor to the metastatic growth by 
creating a permissive environment [118] (Figure 5). Additionally, matrix metalloproteinases 
(MMPs) are also part of the ECM remodeling (Figure 5). Originally, MMP is proposed to 
cause the degradation of the basement membrane which facilitates the tumor cell invasion 
[119]. However, it turns out that MMPs also induce TGF-β production, resulting in the 
establishment of the metastatic-permissive niche and the expression of vascular endothelial 
growth factor (VEGF) that promotes angiogenesis and lymphangiogenesis. In addition, 
MMPs drive inflammation in cancer [119]. All this mechanisms contribute in the promotion 
of tumor progression.  
One notable condition observed in the tumor microenvironment is hypoxia. This condition 
will result in the expression of hypoxia-inducible factors (HIF-1α, HIF-2α, HIF-3α, or HIF-
1β) (Figure 5). HIF-1α is displayed to promote expression of transcription factors responsible 
for tumor growth, vascularization, and metastasis [120]. In addition, the elevated HIF-1α and 
HIF-2α will in turn induce glycolysis [121]. Consequently, as the glycolytic metabolism 
increases, lactic acid production will be elevated, posing to the acidosis condition (Figure 5). 
This acidosis condition is further driven by the pH-regulating systems that maintain the level 
of intracellular pH in order to support cell survival in the tumor microenvironment [122]. 
As mentioned above, tumor microenvironment also consists of recruited cells such as the 
immune cells. Paradoxically, the immune cells in the tumor microenvironment may possess 
pro-tumorigenic features, as proposed in the concept of inflammation-induced cancer [123]. It 
was demonstrated that the innate myeloid cells produce sets of pro-inflammatory cytokines 
that lead to the induction of STAT3 and nuclear factor-κB (NF-κB) in the tumor cells (Figure 
5). This signal activation will promote survival and proliferation of the tumor cells, DNA 
damage, and epithelial-mesenchymal transition (EMT) that facilitates the tumor growth 
[123]. In addition, other chronically-activated innate immune cells, such as macrophages, 
mast cells, and granulocytes present in this microenvironment are also linked in supporting 
tumor development [124].     
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Besides pro-tumoral activities, immune cells elicit anti-tumor responses in the tumor 
microenvironment. However, the success of the anti-tumor immune response depends on how 
well the adaptive immune cells can infiltrate the tumor microenvironment. There are three 
models of immune cell infiltration in the tumor microenvironment. The first model is when 
there is a high infiltration of leukocytes but the cytotoxic lymphocytes (also with low 
expression of activation markers granzyme B and IFNγ) do not enter the tumor core; this is 
called the infiltrated-excluded microenvironment [125]. This condition is indicative of lack 
immune recognition to the tumor [126]. The second model is termed infiltrated-inflamed 
which shows that the cytotoxic lymphocytes infiltrate the tumor core through PD-1 and PD-
L1 ligation, expressed by the lymphocytes and tumor cells, respectively [125]. The last model 
is the extension of the infiltrated-inflamed microenvironment, in which the leukocyte 
Figure 5. The tumor microenvironment. The tumor is supported by the microenvironment which is 
composed of the ECM, residing or recruited cells, and conditions like hypoxia and acidosis. The complex 
interaction among the components of the microenvironment will induce the upregulation of factors inside 
the tumor cells that promote the tumor cell survival and progression. ECM: extracellular matrix, EMT: 
epithelial-mesenchymal transition, HIF: hypoxia-inducible factor, MMP: matrix metalloproteinase, NF-
κB: nuclear factor-κB, STAT3: signal transducer and activator of transcription 3. 
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infiltration will form a tertiary lymphoid structure similar to a lymph node [125]. The tertiary 
lymphoid structure contains other immune cell types beside cytotoxic lymphocytes and may 
correlate with better prognosis for its anti-tumor property [127]. 
Taken together, the dynamics inside the tumor microenvironment resemble a chronic 
inflammation, with its different constituents that may provide positive or negative signals for 
tumor growth. By having a deep understanding of the complex interplay within this 
environment, new targets for cancer immunotherapy may be unveiled. 
 
1.7 TUMOR IMMUNITY     
The concept of tumor immunity has come to be widely acknowledged over the past decades. 
It is believed that the tumor cells are targeted by the immune cells through the recognition of 
two categories of antigens: tumor-specific antigens (antigens that are unique to the tumor 
cells) or tumor-associated antigens (antigens that are not exclusively expressed by the 
particular tumor cells) [128]. This concept gave rise to the tumor immunosurveillance 
hypothesis proposed by Frank M. Burnet, in which the pre-cancerous and cancerous cells are 
recognized and eliminated by the immune cells before causing any harm [129, 130]. 
However, despite the fully functioning immune cells within the body, tumors are still capable 
to grow. Therefore, the concept of immunoediting is better in explaining the interaction 
between tumor and immune cells. 
The immunoediting concept comprises of three phases: 1) elimination, in which the immune 
cells eliminate tumor cells as what has been proposed in the tumor immunosurveillance 
hypothesis, 2) equilibrium, when there is a temporary state of equilibrium between the 
immune cells and the growing tumor, resulting in tumor dormancy, and 3) escape, where the 
tumor is capable to avoid or even suppress the immune cell-mediated tumor destruction, 
leading to further tumor growth [131]. More detailed explanation of each phase is described 
below. 
1.7.1 The elimination phase  
The tumor immunosurveillance has taught us that elimination of the developing tumor cells 
may be optimally executed by the immune cells. This process requires both the innate and 
adaptive immune responses. The elimination phase starts when the innate immune cells such 
as NK cells, NK T cells, γδ T cells, and macrophages are recruited to the tumor site due to 
pro-inflammatory molecules and chemokines produced by the tumor microenvironment 
(Figure 6). Once these cells reach the tumor site, they will recognize the ligands for NKG2D 
expressed on the tumor cells and they start to secrete IFNγ [132]. The major result of IFNγ 
secretion is the destruction of some tumor parts by the innate cells. Furthermore, recruited 
DCs may obtain the tumor antigens by ingesting the tumor cell debris. Subsequently, they 
will migrate to the draining lymph nodes to present the tumor antigens to CD8+ and CD4+ T 
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cells (Figure 6). This event will result in the homing of tumor-specific T cells to the tumor 
which will completely eliminate the remaining tumor cells [131].  
 
 
 
 
 
 
 
 
1.7.2 The equilibrium phase 
The phase of the equilibrium is described to be the longest among the three phases. In here, 
only the adaptive arm of the immune system that plays a significant role to control the 
outgrowth of the tumor cells which survive from the elimination phase. The major control by 
the adaptive immune system is demonstrated to rely on constant IL-12 and IFNγ secretion by 
T cells (Figure 6). The result of this process is the tumor dormancy within the host [133].  
1.7.3 The tumor immune escape 
In the immune escape phase, the tumor cells manage to surpass the equilibrium phase and 
breach the immune defense. Consequently, the tumors can grow further and become 
clinically visible. The capacity of tumors in evading immune destruction is now part of the 
Hallmarks of cancer: the next generation [5]. This condition is the result of the evolving 
cellular and molecular changes within the tumor cells which are heterogeneous among the 
patients and tumor types [134]. Multiple mechanisms utilized by the tumors in avoiding the 
innate and adaptive immune destruction have been discovered in the past few years. This 
heterogeneity of the tumor immune escape will have an impact in the selection of 
immunotherapeutic strategies to target the right escape mechanisms [135]. In here, we will 
discuss some known and newly emerging tumor immune escape mechanisms.  
Figure 6. The tumor immunoediting. The concept of tumor immunoediting consists of three phases. In 
the elimination phase, the innate and adaptive immune cells can eliminate the tumor cells, leading to the 
tumor regression. The next phase is the equilibrium in which the tumor cell growth is controlled by the 
adaptive immune cells, resulting in tumor dormancy. Lastly, the tumors can escape the immune 
destruction by different mechanisms that enable the tumors to grow further. CTLA-4: cytotoxic T 
lymphocyte-associated protein 4, DC: dendritic cell, IFNγ: interferon-γ, IL: interleukin, MDSC: myeloid-
derived suppressor cell, NK: natural killer cells, NKT: natural killer T cells, PD-1: programmed cell 
death 1, PD-L1: programmed death-ligand 1, STAT3: signal transducer and activator of transcription 3, 
TAM: tumor-associated macrophage, TGF-β: transforming growth factor-β, Treg: regulatory T cell. 
 
Adapted from Schreiber RD, et al. Science. 2011 
DC 
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1.7.3.1 Escape through resistance to immune recognition and destruction 
The tumor cells are displayed to possess an elevated rate of somatic mutations, resulting in a 
high generation of neo-antigens [136]. This capacity results in the potential recognition of the 
neo-antigens by T cells that leads to a high T cell infiltration in the tumor tissue during the 
elimination and equilibrium phases. As the tumor evolves, the tumor immune recognition 
may be reduced due to the loss of tumor antigen expression. In this case, the tumor cells can 
stop expressing the antigens that are recognized by T cells [137]. Additionally, the tumor 
cells can also downregulate MHC class I expression on the cell surface, causing the 
impairment of antigen presentation to the CD8+ T cells [138] (Figure 6). Another possible 
mechanism that leads to the loss of tumor antigen expression may be due to disturbed 
antigenic processing inside the tumor cells, such as defected proteosomal unit and peptide 
transporter associated with antigen processing 1 and 2 (TAP-1 and TAP-2) [139]. 
Consequently, the tumor cells are invisible to the T cells and are capable to grow extensively.  
Furthermore, tumor cells can develop insensitivity towards IFNγ due to the abnormality of 
the IFNγ receptor signaling pathway in the tumor cells [140]. Another way of avoiding 
immune destruction can be reached by expressing STAT3, which induces anti-apoptotic 
signals in tumor cells [141] and also mediates immunosuppression [142] (Figure 6). 
Moreover, under glycolytic metabolism in the tumor microenvironment, lactate is produced 
and selectively inhibits FAK family-interacting protein of 200 kDa (FIP200). The loss of 
FIP200 results in the naïve T cell apoptosis which will dampen anti-tumor immune response 
[143]. Recently, it was demonstrated that tumor can also escape immune destruction by 
suppressing TNF cytokine signaling in CD8+ T cells, which further reduces the T cell-
mediated tumor immunosurveillance [144].  
1.7.3.2 Escape through tumor-induced chronic inflammation 
The other immune escape model displays a chronic inflammation induced by the tumors 
which may lead to the expression of tolerogenic molecules and infiltration of suppressive 
cells causing impairment of anti-tumor immune responses [134]. Tumor cells are capable of 
secreting suppressive cytokine TGF-β, which can inhibit the transcription of granzymes and 
perforin encoding-genes in CD8+ T cells [145] (Figure 6). Another tumor-produced molecule 
involved includes VEGF. VEGF can recruit and activate immunosuppressive Tregs and 
myeloid-derived suppressor cells (MDSCs) in the tumor [146].  
Accordingly, Tregs suppress tumor-specific T cells through mechanisms like IL-2 over-
consumption, expression of co-inhibitory molecules CTLA-4, PD-1, and PD-L1, as well as 
secretion of IL-10 and TGF-β [147] (Figure 6). However, evidences indicate that the 
infiltration of Tregs in the tumor has a heterogeneous outcome among tumor types and may 
be linked to a favorable prognosis [95]. MDSCs also inhibit T cells through several 
mechanisms, such as depletion of amino acids (arginine, tryptophan, and cysteine) required 
by T cells to function, TGF-β secretion, and Tregs induction [148] (Figure 6). 
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Another tumor immune escape mechanism is contributed by tumor-associated macrophages 
(TAMs) (Figure 6). Under chronic inflammatory condition, macrophages can be found 
infiltrating the tumors. Correspondingly, infiltrated macrophages are stimulated by IL-4, IL-
13, IL-10, and macrophage colony stimulating factor (M-CSF) from the tumor 
microenvironment, resulting in the polarization towards M2 macrophages instead of M1 
macrophages [135]. TAMs in M2 macrophage phenotype own anti-inflammatory and pro-
tumorigenic properties, as seen by their poor antigen-presenting capacity towards CD8+ T 
cells and their secretion of immunosuppressive cytokines IL-10 and TGF-β [149]. 
Additionally, TAMs express CCL22 that attracts CCR4-expressing Tregs into the tumors 
[150].  
It was also demonstrated that IFNγ produced by tumor-infiltrating CD8+ T cells promotes the 
upregulation of PD-L1 and indoleamine-2,3-dioxygenase (IDO) expression in the tumors. 
These two molecules are responsible for T cell suppression. Moreover, the Treg recruitment 
to the tumors may also be driven by CD8+ T cells which is mediated through CCL22/CCR4 
axis [151]. 
Furthermore, IFNγ-driven PD-L1 expression on tumor cells is utilized by the tumors to 
escape immune destruction through ligation to its ligand PD-1 on T cells, resulting in 
inhibitory signaling pathway (Figure 6). PD-L1 expression is maintained on the cell surface 
of tumor cells by CKLF-like MARVEL trans-membrane domain-containing protein 6 
(CMTM6). CMTM6 acts as a key regulator of PD-L1 that inhibits its degradation in a 
lysosome-mediated fashion, resulting in a persistent PD-L1 expression [152, 153]. 
Chronic inflammatory environment together with continuous antigenic exposure inside the 
tumors will also cause the alteration in the T cell programming that can lead to exhaustion. 
Additionally, it was demonstrated that IL-10 and TGF-β may also regulate T cell exhaustion 
[154]. Exhausted T cells express markers that are distinct to the effector, memory, and naïve 
T cells [155]. Typically, exhausted T cells express multiple inhibitory receptors such as PD-1, 
Tim-3, LAG3, 2B4, CD160, and CTLA-4. The higher co-expression of these receptors 
indicates the more severe exhaustion of T cells [156]. Functionally, exhausted T cells are lack 
of effector functions like proliferation, cytokine production, and cytotoxicity [154, 155]. 
Therefore, even with the possibility of T cells in infiltrating the tumor tissue, as suggested by 
the infiltrated-inflamed tumor model [125], components from the tumor-induced chronic 
inflammation can manage to dampen effector T cell activities by inducing exhausted and 
non-functional T cells. 
In summary, tumor cells utilize various approaches in order to avoid the immune destruction 
(Figure 6) as suggested by Hanahan and Weinberg in the Hallmarks of cancer: the next 
generation [5]. Consequently, the tumors can grow and give a clinical consequence to the 
patients, even though our immune system has a potent element of immunosurveillance. The 
heterogeneous nature of tumor immune escape mechanisms among patients and cancer types 
may be used as targets in pursuing tailored cancer immunotherapy in the future. 
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2 AIMS OF THE THESIS 
The general aim of this thesis was to investigate the modulation of T cells in the tumor 
microenvironment of solid tumors, in order to find potential targets in cancer immunotherapy. 
The specific aims of each paper were as follows: 
 
Paper I. To investigate whether FOXP3+ CD4+ T cells in the tumors were committed 
regulatory T cells (Tregs) and to examine the functions of the tumor-infiltrating Tregs. 
 
Paper II. To characterize the cytotoxic capacity of the tissue-resident memory T (TRM) cells 
in the tumors by DNA methylation profiling and correlate it with their phenotypes.  
 
Paper III. To identify the tumor immune escape mechanisms on CD8+ T cells from the 
tumor-draining sentinel lymph nodes. 
 
Paper IV. To evaluate the effects of neoadjuvant chemotherapy (NAC) on the phenotypes 
and functions of T cells from tumor-draining sentinel lymph nodes. 
 
Paper V. To explore an alternative method to detect micrometastases in the sentinel lymph 
nodes using flow cytometry. 
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3 METHODOLOGICAL APPROACH 
This chapter contains a summary of materials and underlying methodologies used in the 
studies included in this thesis. A detailed description of this account is displayed in the 
materials and methods section of each paper (I-V). 
 
3.1 PATIENTS 
3.1.1 Cancer patients 
3.1.1.1 Urinary bladder cancer (Paper I, II, III, and IV) 
In total, 99 patients diagnosed with urothelial urinary bladder cancer (UBC) were recruited in 
the four prospective studies (Paper I-IV) from participating hospitals in Sweden between the 
years 2013-2018. Paper I included 46 patients, paper II included 53 patients, paper III 
included 42 patients, and paper IV included 40 patients. The mean age of the patients was 70 
years old (range 50-87). 29 patients were female and 70 patients were male. Following 
clinical diagnosis, the patients underwent TUR-B and the patients diagnosed with muscle 
invasive tumors would proceed to radical cystectomy. Neoadjuvant chemotherapy (1-4 
cycles) was administered to eligible patients prior to radical cystectomy, consisting of 
Methotrexate, Vinblastine, Adriamycin, and Cisplatin (MVAC).  
3.1.1.2 Renal cancer (Paper V) 
Five patients (three females and two males) diagnosed with renal tumors were included in 
this study from two participating hospitals in Sweden. The mean age of the patients was 61 
years old (range 47-69). Four patients were diagnosed with malignant tumors and one patient 
with benign tumor. All the patients underwent nephrectomy, in which removal of tumor and 
tumor-surrounding lymph nodes took place.  
3.1.1.3 Cancer patient samples 
From UBC patients, we received peripheral blood and tumor tissues at the time of TUR-B. 
Meanwhile, at radical cystectomy, we obtained peripheral blood, lymph nodes, and in some 
cases, tumor tissues. In renal cancer patients, we received peripheral blood, lymph nodes, and 
tumor tissues at the time of nephrectomy. 
Lymph nodes were identified as tumor-draining sentinel nodes (SNs) using radioactive tracer 
99mTechnetium, injected during cystectomy or nephrectomy [157]. The injection was 
performed in the area surrounding the tumor and the radioactivity of each lymph node was 
measured using a handheld Geiger counter. Nodes with positive radioactive signal were 
classified as tumor-draining SNs. 
All the samples were processed to acquire single cell suspensions. Peripheral blood 
mononuclear cells (PBMCs) were isolated from peripheral blood using a density gradient 
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centrifugation (Ficoll-Paque Plus). The tumor-infiltrating immune cells were extracted from 
the tumor tissues by a mechanical disruption using the GentleMACS instrument together with 
an enzymatic digestion by collagenase/hyaluronidase and DNAse I. The cells from lymph 
nodes were isolated by gentle pressure homogenization through a 40 μM cell strainer.  
The cells isolated from all the samples were subjected to T cell phenotype investigations at 
steady state and after in vitro-stimulated conditions by epigenetic analysis (Paper I, II, and 
IV), gene expression analysis (Paper III), and protein expression analysis (Paper I, II, III, and 
IV). Finally, single cell suspensions from lymph nodes were investigated for the presence of 
micrometastatic tumor cells (Paper V).   
3.1.2 Healthy donors (Paper I, II, III, and V) 
We received leukocytes-enriched whole blood (buffy coat) of healthy donors from 
Karolinska University Hospital Blood Bank. PBMCs were isolated from the buffy coat by a 
density gradient centrifugation (Ficoll-Paque Plus) and were used in experimental setups and 
in vitro studies. For experimental setups, healthy donor PBMCs were used for the 
identification of the perforin gene (PRF1) reporter CpG site (Paper II) and for the 
optimization of the micrometastasic detection method (Paper V). Meanwhile, in vitro studies 
were carried out in the investigation of Treg effect on the MMP2 suppression (Paper I), 
stimulation of sorted CD8+ T cells using 5-Azacytidine (Paper II) and UBC cell line 
supernatant (Paper III), and in the validation of proteomic analysis (Paper III).  
 
3.2 CELL LINES (PAPER I, III, AND V) 
In paper I and III, we used two UBC cell lines, RT4 and 5637. RT4 is a non-muscle invasive 
cancer cell line, whereas 5637 is a muscle invasive cancer cell line. The expression of MMP2 
was measured on 5637 cells after co-culture with Tregs (Paper I). Furthermore, the 
supernatant from RT4 and 5637 cell line cultures were used to stimulate CD8+ T cells from 
healthy donor PBMCs in vitro to demonstrate the effect of tumor immune escape mechanism 
from muscle invasive UBC (Paper III). 
In paper V, we worked with three kinds of renal cancer cell lines, which were RCC4, ACHN-
3, and CAKI-6. The cell lines were used for the optimization of micrometastatic detection by 
flow cytometry since they express tumor cell markers cytokeratin 18 (CK18), CA9, and 
Cadherin 6 (Cad6). The optimization was performed by spiking these three cell lines into 
PBMCs from healthy donors in known concentrations. The amount of positive cells was 
measured by flow cytometry. 
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3.3 CELL SORTING (PAPER I, II, III, AND IV) 
Cells isolated from peripheral blood, lymph nodes, and tumors were sorted for different cell 
subsets. Initially, the cells were magnetically sorted using CD3, CD8, CD4, or CD14 
EasySep positive selection kits. Positively selected cells were then subjected to sorting by 
flow cytometry after staining with fluorescence-conjugated antibodies.  
Throughout the studies, we sorted for bulk CD8+ T cells (Paper II, III, and IV), different 
memory CD8+ T cell subsets such as TRM (CD8+ CD103+), TCM (CD8+ CD45RA- CCR7+), 
TEM (CD8+ CD45RA- CCR7-), and TEMRA (CD8+ CD45RA+ CCR7-) cells (Paper II), as well 
as perforin+ or perforin- CD8+ T cells (Paper II). Additionally, CD4+ T cells were sorted into 
effector T cells (Teffs) (CD4+ CD25- CD127+) or Tregs (CD4+ CD25+ CD127-) (Paper I). 
For sorting based on an intracellular marker like perforin (Paper II), magnetically selected 
CD8+ T cells were firstly stained for surface markers by fluorescence-conjugated antibodies. 
Next, the cells were fixated using HOPE I Fixation solution (DCS Innovative Diagnostik-
Systeme) overnight in 0-4oC. This fixation protocol has the advantage of not causing any 
degradation of the nucleic acids as our readouts, compared to formaldehyde-based fixation 
solution. Following fixation, the cells were permeabilized using 0.1% saponin and 
intracellularly stained using anti-perforin antibody for sorting by flow cytometry.   
 
3.4   IN VITRO CELL STIMULATION 
All in vitro T cell stimulation assays throughout the studies were performed in RPMI medium 
supplemented with 10% fetal calf serum (FCS), 1% l-glutamine, and 1% 
penicillin/streptomycin (Paper I) or AIM-V medium (Paper II, III, and IV). The cells were 
incubated at 37oC with 5% CO2.  
3.4.1 Regulatory T cell suppression assay (Paper I) 
In order to investigate the suppressive capacity of Tregs, sorted Tregs (CD4+ CD25+ CD127-) 
from PBMCs and tumors of UBC patients were co-cultured with Teffs (CD4+ CD25- 
CD127+) as responder cells. The co-culture was performed in the presence of anti-Biotin 
beads loaded with biotinylated CD2, CD3, and CD28 antibodies to stimulate responder Teffs. 
Teffs were pre-labeled using carboxyfluorescein succinimidyl ester (CFSE) and the 
proliferation following 72 hours of co-culture, measured as the dye dilution, was used as the 
readout. 
3.4.2 Treg suppression on MMP2 expression assay (Paper I) 
Isolated Tregs were co-cultured with either differentiated M2-like macrophages or 5637 UBC 
cell line in order to investigate the suppressive effect of Tregs on MMP2 expressed by TAMs 
and UBC tumor cells. M2-like macrophages were differentiated from healthy donor PBMC 
CD14+ monocytes by providing M-CSF stimulation for six days [158]. In parallel, isolated 
Tregs were stimulated using anti-Biotin beads loaded with biotinylated CD2, CD3, and CD28 
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antibodies for six days. Activated Tregs were then added at different ratios to the M2-
macrophage or 5637 cell cultures. At different time point, culture supernatants were collected 
and adhered M2-macrophages and 5637 cells were acquired after Treg removal for reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.  
3.4.3 5-Azacytidine (Paper II) 
We used the demethylating agent 5-Azacytidine (5-aza) to treat cultured CD8+ T cells and 
investigate the effect of DNA methylation on perforin transcriptional regulation. 5-aza acts by 
binding irreversibly to the DNA methyltransferase (DNMT), resulting in loss of methylation 
of the daughter cells [159]. In this experiment, isolated CD8+ T cells from healthy donor 
PBMCs were activated by TCR stimulation, using plate-coated anti-CD3 and soluble anti-
CD28 stimulating antibodies, in the presence of recombinant human IL-2 for 48 hours. The 
cells were then treated with 5-aza for 48 hours, with additional 48 hours of culture without 
the presence of 5-aza. Perforin expression was assessed by flow cytometry at the end of the 
culture. 
3.4.4 Tissue-resident memory T cell activation assay (Paper II) 
Isolated TRM cells (CD8+ CD103+) from PBMCs and tumors of UBC patients were activated 
using recombinant human IL-15 and TCR stimulation using plate-coated anti-CD3 and 
soluble anti-CD28 stimulating antibodies for 48 hours. At the end of culture, the cells were 
phenotyped by flow cytometry and investigated for their PRF1 DNA methylation status by 
pyrosequencing. 
3.4.5 Tumor homogenate stimulation (Paper III and IV) 
In order to evaluate the response of SN-derived T cells from UBC patients towards tumor 
antigen, we stimulated these cells using autologous tumor homogenate for seven days. Tumor 
homogenate was used as the tumor antigenic source and it was prepared as described in paper 
III. Following seven days of culture, flow cytometry was performed to phenotype T cells 
(Paper III and IV). In addition, stimulation index (SI) was counted from the ratio of CD4+ 
lymphoblasts to CD4+ lymphocytes, as adapted from Flow cytometric Assay for Specific 
Cell-mediated Immune response in Activated whole blood (FASCIA) protocol (Paper IV) 
[160]. 
3.4.6 Tc1-promoting stimulation (Paper III) 
To investigate the feasibility in restoring perforin expression in CD8+ T cells from SNs of 
UBC patients, we stimulated these cells in Tc1-promoting conditions. Isolated CD8+ T cells 
from SNs were cultured in the presence of recombinant human IL-12 and IL-2, neutralizing 
anti-IL-4 antibody, and TCR stimulation using plate-coated anti-CD3 and soluble anti-CD28 
stimulating antibodies. After seven days, cells were phenotyped by flow cytometry and RT-
qPCR. 
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3.4.7 UBC cell line supernatant stimulation and proteomic analysis 
validation (Paper III) 
For evaluating the tumor immune escape mechanism by tumor cells, we stimulated healthy 
donor CD8+ T cells from peripheral blood using the culture supernatant of RT4 and 5637 cell 
lines for five days. The culture supernatants were collected from the cell line cultures, in 
which we used RPMI-Serum and phenol red free medium (SFM) in the last 24 hours of 
culture, so that we did not have the contamination of serum-derived proteins in the 
downstream mass spectrometry (MS) analysis. The stimulated CD8+ T cells were then 
harvested after five days of UBC cell line supernatant stimulation and phenotyped by flow 
cytometry and RT-qPCR. Meanwhile, the culture supernatants from both cell lines were 
analyzed for their proteomic profile using mass spectrometry (LC – MS/MS).  
Following MS analysis, we validated the effects exerted by the identified proteins exclusively 
expressed by the muscle invasive 5637 cell lines (ICAM-1 and TGF 2) on CD8+ T cells. 
Healthy donor PBMC CD8+ T cells were stimulated using plate-coated ICAM-1 Fc chimera 
and soluble TGF 2, in the presence of anti-CD3 stimulating antibodies. After five days of 
culture, we analyzed the cells using flow cytometry and RT-qPCR. 
 
3.5   EPIGENETIC – DNA METHYLATION ANALYSIS  
3.5.1 Genomic DNA extraction and bisulfite conversion (Paper I, II, and IV) 
We investigated the DNA methylation status in the regulatory regions of FOXP3 encoding 
gene FOXP3 (Paper I), perforin encoding gene PRF1 (Paper II and IV), and IFNγ encoding 
gene IFNG (Paper IV). Genomic DNA (gDNA) from Tregs and CD4+ Teffs (Paper I), as well 
as CD8+ T cells (Paper II and IV) was extracted and bisulfite-converted using the EZ DNA 
Methylation Direct kit. Bisulfite treatment will convert unmethylated cytosine residues into 
uracil and subsequent polymerase chain reaction (PCR) will convert uracil into thymine 
residues. Conversely, methylated cytosine residues will remain unchanged after bisulfite 
treatment. 
3.5.2 TA cloning and bisulfite sequencing (Paper II) 
In order to identify the PRF1 reporter CpG site, we used the TA cloning method, followed by 
bisulfite sequencing. The advantage of using this method is the possibility to evaluate DNA 
methylation status from a single cell, which is essential when predicting the CpG site 
responsible to regulate PRF1 transcription. In here, we assessed the DNA methylation status 
of PRF1 enhancer region from perforin+ and perforin- PBMC-derived CD8+ T cells. The 
enhancer region of PRF1 from the bisulfite-converted DNA was PCR-amplified, TA-cloned 
into pCR4-TOPO vector, and transformed into TOP10 E. coli. Next, DNA from each colony 
representing a single cell was Sanger sequenced to determine the DNA methylation status 
from each cell subset.  
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3.5.3 Pyrosequencing (Paper I, II, and IV) 
The benefit of using pyrosequencing method is the possibility to sequence the bisulfite-
converted DNA directly on the PCR amplicons without TA-cloning. However, the result of 
this sequencing protocol will be an accumulative DNA methylation percentage of each CpG 
site from all cells. The reporter CpG sites of FOXP3 [92, 93], PRF1, and IFNG [161] were 
pyrosequenced from PCR amplicons, in which one of the PCR primer pairs was biotinylated 
to ensure specificity of the amplicons to be sequenced.  
 
3.6 GENE EXPRESSION ANALYSIS  
3.6.1 Microarray analysis (Paper I) 
Gene expression analysis by microarray was performed from messenger RNA (mRNA) 
isolated from tumor tissues of UBC patients. Isolated mRNA was amplified and labeled using 
GeneChip WT PLUS Reagent kit resulting in cDNA product that was hybridized to 
Affymetrix GeneChip Human Transcriptome 2.0 arrays. The microarray data were deposited 
in the EMBL-EBI database. 
3.6.2 Reverse transcription – quantitative PCR (RT-qPCR) (Paper I and III) 
RT-qPCR was used to measure the gene expression coded in mRNA. Isolated mRNA was 
reverse-transcribed into cDNA and run under RT-qPCR protocols using SYBR Select. We 
evaluated the expression of MMP2 gene in M2-macrophages and 5637 UBC cell line after 
co-culture with Tregs (Paper I), as well as GZMB, PRF1, TBX21, and GATA3 genes in CD8+ 
T cells from PBMCs, SNs, and tumors of UBC patients (Paper III). GAPDH or RPII were 
used as the housekeeping genes. The gene expression level was calculated using the ∆∆Ct 
formula.  
 
3.7 PROTEIN ANALYSIS 
3.7.1 Flow cytometry (Paper I, II, III, IV, and V) 
Multiparameter flow cytometry method enables us in measuring the expression of the surface 
and intracellular cell markers. Fluorescence-conjugated antibodies were used to label the 
specific epitopes of the cell markers. For intracellular marker staining, the cells were first 
fixed and permeabilized before staining with the antibodies.   
In paper I, II, III, and IV, we used flow cytometry to phenotype T cells from samples 
obtained from the UBC patients. Meanwhile, in paper V, we used flow cytometry as a 
method to detect micrometastases in lymph nodes of patients with renal tumors based on the 
tumor cell marker expression. All the flow cytometry data were acquired using LSRFortessa 
II instrument and analyzed using FlowJo software. 
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3.7.2 Enzyme-linked immunosorbent assay (ELISA) (Paper I and III) 
The ELISA method was used to measure the amount of secreted soluble MMP2 from M2-
macrophages and 5637 UBC cell line after co-culture with Tregs (Paper I), as well as perforin 
and granzyme B from CD8+ T cells derived from PBMCs and SNs of UBC patients after 
tumor homogenate stimulation (Paper III). The culture supernatants were obtained at the 
given time points and analyzed using ELISA. Sandwich ELISA was used in these studies 
with capture antibodies and secondary antibodies against MMP2, perforin, and granzyme B. 
The concentration of proteins in the culture supernatants were calculated based on the 
standard curve for each protein.  
3.7.3  Liquid chromatography – mass spectrometry (LC – MS/MS) (Paper III) 
We used LC – MS/MS for our proteomic analysis in identifying the secreted proteins from 
the culture supernatants of UBC tumor cell lines (RT4 and 5637). The LC – MS/MS was 
performed using a Dionex UltiMate™ 3000 RSLCnano System coupled to a Q-Exactive 
mass spectrometer. The LC system separates the proteins, while MS provides the structural 
identity of the analytes. The acquired raw data from the LC – MS/MS run were analyzed 
using Sequest-Percolator or Target Decoy PSM Validator under the Proteome Discoverer 1.4 
software platform against human Uniprot database. 
  
3.8 BIOINFORMATIC DATA ANALYSIS 
3.8.1 KEGG pathway analysis (Paper I) 
Transcriptomic data from the microarray analysis were calculated using partial least squares 
(PLS) analysis for standardized coefficients of Treg influence on individual gene expression. 
The calculations (loadings) were then plotted against KEGG pathway for UBC using the R 
platform.   
3.8.2 ViSNE (Paper II) 
ViSNE was used to analyze and visualize high dimensional multiparameter data from flow 
cytometry. In this study, we exported manually gated CD8+ T cell data with compensated 
parameters using FlowJo software. The exported data were analyzed using CYT tool [162] on 
the MATLAB platform. The measured fluorescence intensity of the parameters used in the 
analyses was transformed using the arcsin function with a cofactor of 150. All groups of the 
samples were adjusted to have a comparable number of events. ViSNE analysis was 
performed using the Barnes-Hut Stochastic Neighbor Embedding (bh-SNE) algorithm to map 
the events.  
3.8.3 Network analysis using STRING database (Paper III) 
The proteins identified from LC – MS/MS analysis were analyzed for their interaction using 
the STRING network analysis. First, proteins categorized under the Gene Ontology (GO) 
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term “immune system process” were selected and the known protein-protein interactions 
from the STRING database were used to produce a network graph using igraph [163] on the 
R platform. The size was used to represent the differential relative expression between RT4 
and 5637 proteomic components and the color indicators represented the influence of the 
protein position in the network (betweenness). Davidson Harel algorithm was used for the 
layout of the network graph. 
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4 RESULTS AND DISCUSSION 
This thesis aims to investigate the modulation of T cell phenotypes in the solid tumor 
microenvironment. We build our fundamental investigation starting from the molecular to 
cellular level, in the hope to identify novel strategies for cancer immunotherapy in the future.  
There are two important sites of the tumor microenvironment: the primary tumor tissues and 
the tumor draining sentinel nodes. In paper I and paper II, we focus on the primary tumor 
site. Here, we investigated how the Tregs played a role in regulating the tumor invasiveness 
(Paper I) and how TRM cells, as the most dominant subset of CD8+ T cells in the tumors, had 
a protective effect as displayed by their epigenetic commitment of cytotoxicity (Paper II).  
We next sought to understand the microenvironment in the sentinel nodes. In here, we first 
demonstrated how tumor immune escape caused the cytotoxicity of CD8+ T cells to be 
compromised (Paper III). Moreover, we described that the standard neoadjuvant 
chemotherapy could promote the anti-tumor T cell responses (Paper IV), which was 
discovered to be suppressed by the tumors in paper III. Furthermore, the implication of the 
tumor immune escape mechanisms is the opportunity for tumors to progress and metastasize 
into sentinel nodes. We here revealed that the micrometastatic cells in the sentinel nodes 
could be detected using flow cytometry (Paper V), allowing for an objective, time-efficient, 
and standardized method for staging metastatic dissemination in the lymph nodes. 
In this section, all the key findings are explained and discussed further. The detailed account 
for each study can be acquired from the original constituent papers.  
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4.1 REGULATORY T CELLS MAY REGULATE TUMOR INVASIVENESS BY 
SUPPRESSING MMP2 (PAPER I) 
Tregs have been known to suppress anti-tumor immune response [164]. However, this 
paradigm starts to be shifted, since not all of the cancers display a poor prognosis when 
having a high infiltration of Tregs in the tumors [165]. Previously, we have demonstrated that 
in UBC, a high number of FOXP3+ tumor infiltrating lymphocytes (TILs) correlates with an 
improved patient survival [166]. From this surprising finding, we first argued that FOXP3 is 
not only a marker of Tregs, but also can be expressed by activated conventional Teffs 
transiently [91], which accordingly would explain the positive prognosis.  
Nevertheless, we further asked the question whether tumor FOXP3+ T cells conferred a 
committed Treg phenotype. To answer this, we performed an epigenetic analysis by means of 
DNA methylation to determine the lineage commitment of FOXP3+ CD4+ T cells as Tregs. 
We investigated the CpGs at the two regulatory regions of the FOXP3 gene: the promoter 
[92] and the conserved non-coding sequence 2 (CNS2) [93] regions. CpG hypomethylation of 
these two regions are previously proven to mark a specific and stable Treg status. Our finding 
displayed that sorted Tregs (CD4+CD25+CD127-) from the UBC tumors were 
hypomethylated in both promoter and CNS2 CpG sites compared to the Teffs (CD4+CD25-
CD127+) (Figure 7). This methylation status was most pronounced at the CpG position -77 in 
the promoter region, as described before [92]. Additionally, we validated the Treg stability, as 
indicated by this epigenetic profile, by performing a long-term culture of tumor Tregs using 
IL-2 stimulation alone and assessed the inheritability of FOXP3 expression [167]. We 
observed that at the end of the culture (day 14), FOXP3 was stably expressed by the Tregs. 
Hence, it indicates that tumor FOXP3+ CD4+ T cells are committed Tregs and not activated 
conventional Teffs.  
 
 
 
 
Figure 7. Lower DNA methylation of FOXP3 regulatory regions in Tregs. The DNA methylation 
status of CpGs located in the promoter and CNS2 regions of the FOXP3 gene is compared between Tregs 
(CD4+CD25+CD127-) and Teffs (CD4+CD25-CD127+) infiltrating the UBC tumors. The mean 
methylation percentage of each CpG site is displayed with the error bars indicating SEM. CNS2: 
conserved non-coding sequence 2, CpG: cytosine-phosphate-guanine, SEM: standard error of the mean, 
Teffs: effector T cells, Tregs: regulatory T cells, UBC: urinary bladder cancer. 
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Furthermore, we phenotyped tumor FOXP3+ CD4+ T cells and demonstrated that these cells 
significantly expressed activated Treg markers, such as CD45RO, HLA-DR, CD69, CTLA-4, 
and CD39. In addition, FOXP3+ CD4+ T cells from the tumors worked functionally as Tregs, 
as exhibited by their capacity to increase pSTAT5 expression following IL-2 stimulation, 
their suppressive effect towards the Teffs, and their low expression of IFNγ and IL-2. Taken 
together, we have proven that FOXP3+ CD4+ T cells infiltrating the tumors are epigenetically, 
phenotypically, and functionally Tregs. 
In the later part of the study, we prompted to investigate on how committed Tregs in the 
tumors had a positive effect to the patient survival. First, we observed that the Treg frequency 
was lower in the invasive front of the tumors compared to the central part in patients with 
muscle invasive UBC. Second, a lower number of Tregs in the invasive front of the tumors 
displayed a worse survival outcome of the patients. Consequently, we started to understand 
that Tregs may have a protective role in inhibiting the tumor invasion. Furthermore, we 
performed a transcriptomic analysis demonstrating that MMP2 was the most influenced gene 
by the Tregs, as shown in the KEGG pathways. Accordingly, we validated that Tregs 
suppressed the expression of MMP2 both in TAMs and tumor cells.  
MMP2 has been identified to support the UBC tumor invasiveness [168-170]. The MMPs are 
expressed by the tumor cells and the surrounding stroma [171, 172]. MMPs function by 
degrading the extracellular matrix [173], as well as modulating neo-angiogenesis and cell 
motility when highly expressed in the invasive front of the tumor tissues [174]. These 
processes will facilitate the tumor invasion. Altogether, as our data suggest that MMP2 
expression in both TAMs and tumor cells is suppressed by the Tregs, it therefore answers our 
question regarding the paradoxical protective effect of Tregs in UBC.  
Although the conclusion to draw this causal relationship was based on in vitro analysis using 
cell line, we somehow could predict how Tregs, in the UBC setting, had a protective role by 
regulating tumor invasiveness. Moreover, this data was supported by our ex vivo analysis that 
made the conclusion stronger.  
In conclusion, we have answered our previous questions of why and how FOXP3+ T cells 
infiltrating the tumors provided a beneficial factor for survival of UBC patients. We discover 
that tumor FOXP3+ CD4+ T cells are committed Tregs which regulate tumor invasiveness by 
suppressing MMP2 expression in TAMs and tumor cells. This novel understanding may 
assist us in finding a new strategy of cancer immunotherapy by targeting this axis in the 
future.  
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4.2 TISSUE-RESIDENT MEMORY T CELLS IN THE TUMORS ARE 
EPIGENETICALLY CYTOTOXIC AND NOT TERMINALLY EXHAUSTED 
(PAPER II) 
One of the valuable assets of the TRM cells is their location in non-lymphoid tissues [65]. 
Consequently, TRM cells are the first barrier of T cells to respond rapidly against tumor cells 
in the tissues, compared to the other CD8+ T cell subsets [73]. Upon antigen encounter, TRM 
cells have been reported to provide recruiting signals, such as IFNγ, IL-2, and TNF [175]. 
TRM cells also promote vascular cell adhesion molecule 1 (VCAM1) upregulation in blood 
vessel endothelial cells [176]. These will result in the recruitment of immune cells including 
NK cells, DCs, and other memory CD8+ T cells [177, 178].  
However, less is known whether TRM cells are effective killers against the tumor cells. The 
study performed in human lung cancer reveals that TRM cells residing in the tumor correlate 
with cytotoxic features, such as granzymes and perforin expression [179]. On the contrary, 
TRM cells are demonstrated to express exhaustion markers PD-1, Tim-3, and LAG3 [180], 
which makes it paradoxical to link TRM cells to cytotoxic activity. Taking this into account, 
an analysis of TRM cell commitment with regards to the cytotoxic capacity from an epigenetic 
angle, despite having signs of exhaustion needs to be investigated.  
In this study, we identified the reporter CpG site (-1053bp upstream of transcription start 
site/TSS) for the perforin gene (PRF1) transcription which was located in the enhancer 
region. Furthermore, we discovered that tumor TRM cells in the UBC were epigenetically 
available for perforin transcription. This was marked by a lower DNA methylation of the 
PRF1 reporter CpG site in tumor TRM cells (mean methylation=32.9%) when compared to 
TRM cells found in the PBMC (mean methylation= 66%) (Figure 8A). Correspondingly, 
tumor TRM cells displayed a higher expression of perforin protein (Figure 8B). As suggested 
previously [180], we observed that 79% of tumor TRM cells expressed the exhaustion marker 
PD-1, which came with a low number of TRM cells that expressed T cell activation marker T-
bet (mean=11.4%). This high number of PD-1+ TRM cells was not seen in PBMC. 
Knowing that tumor TRM cells were epigenetically regulated to be cytotoxic despite having 
signs of exhaustion, we attempted to assess the functional capacity of TRM cells residing in 
the tumors. Isolated TRM cells from tumor tissues were activated in vitro using IL-15 and 
TCR stimulation (stimulating anti-CD3 and anti-CD28 antibodies) for 48 hours. Following in 
vitro stimulation, the number of perforin-expressing tumor TRM cells increased by two-fold 
compared to the non-exhausted TRM cells from PBMC and the unstimulated tumor TRM cells 
(Figure 8C). Additionally, the frequency of PD-1+ T-bet+ TRM cells from the tumors 
increased together with the number of Ki-67-expressing tumor TRM cells when compared to 
the unstimulated condition. This is in line with a previous study using a viral infection in a 
skin model [178]. Therefore, we suggest that TRM cells from the tumors are not terminally 
exhausted despite of their phenotype, which consequently allows their functional cytotoxic 
capacity. Further study to assess activated TRM cell cytotoxic function in killing the 
autologous tumor cells can be addressed using an in vitro killing assay in the future.  
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The reason of why cytotoxic TRM cells expressed the exhaustion marker PD-1 needs further 
studies beyond what is known to be a result of a chronic antigenic exposure in the tumor 
microenvironment [154]. We can nevertheless speculate that PD-1 is a mere TRM cell marker 
that does not affect the cell functionality, since permanent PD-1 expression is epigenetically 
imprinted [181] and antigen-independent [182], as seen in the chronic infection. Accordingly, 
our data also suggested that the frequency of PD-1+ TRM cells was not different between 
tumor stages.   
Furthermore, we demonstrated that TRM cells were the most dominant and cytotoxic memory 
subset of CD8+ T cells in the tumor tissue, accounting for 56.8% population. Importantly, the 
higher number of TRM cells residing within the tumor correlated with a lower tumor stage of 
the UBC patients (n=10). This further validates the protective role of TRM cells, which has 
previously been linked with an improved survival in various cancer patients [183-186]. 
The limiting factor of this study was the low number of patients (n=10) that we could 
correlate between the tumor stages and the frequency of TRM cells. The reason was due to a 
Figure 8. Tumor TRM cells are epigenetically cytotoxic and not terminally exhausted. (A) The mean 
DNA methylation of PRF1 reporter CpG site (-1053bp upstream TSS) is compared between TRM cells 
from PBMC and tumor (n=10). Independent t-test was used as the statistical test. (B) The expression of 
perforin in TRM cells from PBMC and tumor was measured by flow cytometry. (C) Tumor TRM cells 
were stimulated in vitro using IL-15, anti-CD3 and anti-CD28 stimulating antibodies for 48 hours. The 
frequency of perforin-expressing tumor TRM cells was measured by flow cytometry and compared to the 
unstimulated control (n=3). Independent t-test was used as the statistical test. CpG: cytosine-phosphate-
guanine, IL-15: interleukin-15, PBMC: peripheral blood mononuclear cell, TRM: tissue-resident memory 
T cells, TSS: transcription start site. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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restricted number of UBC patients recruited to this study, which fell into the category of stage 
I-III. However, we could recapitulate the trend in which the frequency of TRM cells was 
linked to a lower tumor stage and further demonstrated the protective anti-tumor property of 
TRM cells.  
To conclude, epigenetic profiling of the perforin locus by means of DNA methylation adds to 
our current understanding that TRM cells guarding the tumor tissues are committed to be 
cytotoxic and helps us to find a clue that they are not terminally exhausted. Since a high 
infiltration of TRM cells is linked to a better prognosis, it implicates to the possibility to target 
TRM cells for future translational applications of cancer immunotherapy.  
 
4.3 TUMOR MAY ESCAPE IMMUNE DESTRUCTION BY SUPPRESSING 
PERFORIN EXPRESSION IN CD8+ T CELLS (PAPER III) 
CD8+ T cell has a significant role in the anti-tumor immunity. It is part of the adaptive 
immune response and it has the capacity to kill tumor cells using its cytotoxic constituents, 
such as perforin and granzymes [33]. However, as tumors develop, they have the capability to 
escape the immune destruction, which is part of the cancer immunoediting process [133]. 
This immune attack avoidance by the tumor cells is now integrated in the Hallmark of cancer: 
the next generation, proposed by Hanahan and Weinberg [5]. 
There are several tumor immune escape mechanisms described in solid tumors [134, 136, 
138, 154, 187]. However, the mechanism of tumor escape that affects CD8+ T cell 
cytotoxicity residing in the tumor-draining SNs has not been investigated. SN is an 
interesting site to study CD8+ T cells since SNs receive a high lymphatic flow from the 
tumors due to the high pressure of interstitial fluid and the neo-lymphangiogenesis [188]. 
Therefore, SNs have a high reception of tumor signals and cytokines from the primary tumor, 
which may modify SN CD8+ T cells to be tolerogenic as an escape mechanism [189]. 
In this study, we unveiled a novel mechanism on how UBC tumors may suppress the 
cytotoxicity of SN-derived CD8+ T cells. Our finding displayed that perforin was not 
expressed in SN CD8+ T cells, meanwhile granzyme B expression was preserved (Figure 
9A). We discovered that the low perforin expression was originated from the transcript 
(PRF1 gene) level, which was also seen to be downregulated in the tumor-derived CD8+ T 
cells. Similarly, this phenotype was previously reported in the lung adenocarcinoma [190]. 
Hence, this discovery implies that the cytotoxicity of CD8+ T cells from SNs is compromised. 
Next, we prompted to investigate the phenotype of perforin-deficient (granzyme B+/perforin-) 
CD8+ T cells from the SNs. Perforin-deficient CD8+ T cells were 85% TEM cells, where the 
majority of these cells were PD-1+ (mean=65%), suggesting exhaustion. Consequently, 
perforin-deficient CD8+ T cells had a low expression of the Tc1 transcription factor T-bet 
(mean=25.5%). Furthermore, we demonstrated that in SN CD8+ T cells, the Tbet encoding 
gene TBX21 transcript was downregulated, alongside the upregulation of the Tc2 
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transcription factor GATA3 transcript. Altogether, this indicates that perforin-deficient CD8+ 
T cells from SNs are exhausted TEM cells with a Tc2 anti-inflammatory phenotype. 
 
 
 
 
 
 
 
 
 
Exhaustion in CD8+ T cells is caused by a chronic antigenic exposure formed by the tumor 
microenvironment [191, 192]. The exhausted T cells will have lower effector capacities, due 
to the inhibition of the TCR-induced phosphorylation of ZAP70/CD3δ [193] and CD28 
[194], as well as the suppression of the PI3K, AKT, and RAS pathways [195]. These events 
may lead to the restriction of Tbet expression [196], as seen in our data. Consequently, since 
Tbet expression was decreased, it may have an impact in the low perforin expression, since 
Tbet regulates perforin transcription by binding to its promoter region [197]. 
Further investigation was performed to ascertain the mechanism exerted by the UBC tumor 
cells that caused perforin suppression. We set up an in vitro assay where we cultured sorted 
CD8+ T cells in the presence of culture supernatants from the UBC cell lines: RT4 (non-
muscle invasive) and 5637 (muscle invasive). Muscle invasive UBC supernatant was 
Figure 9. UBC tumors may suppress perforin expression in CD8+ T cells via ICAM-1/TGFβ2-
mediated pathway. (A) The expression of perforin and granzyme B in SN CD8+ T cells was measured 
by flow cytometry. The data from a representative patient is displayed in a density plot with the 
frequency of perforin- and granzyme B-expressing CD8+ T cells shown. (B)(C) CD8+ T cells from 
healthy donor PBMCs (n=3) were stimulated in vitro using TGFβ2, ICAM-1, and anti-CD3 stimulating 
antibody for five days. At day 3 and day 5, in vitro stimulated cells were measured by flow cytometry. 
The expression of perforin (B) and the mean frequency of granzyme B+/perforin- CD8+ T cells (C) were 
compared between stimulated cells and unstimulated control. The error bars in (C) indicate SEM and 
paired t-test was used as the statistical test. ICAM-1: intercellular adhesion molecule 1, PBMC: 
peripheral blood mononuclear cell, SEM: standard error of the mean, SN: sentinel node, TGFβ2: 
transforming growth factor β2. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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displayed to downregulate perforin gene and protein expression, compared to its counterpart. 
Subsequently, we conducted a proteomic analysis using MS, in which we discovered that 
ICAM-1 and TGFβ2 were the two proteins that were present only in the culture supernatant 
of muscle invasive UBC cell line. We validated this finding in vitro and observed that both 
ICAM-1 and TGFβ2 suppressed the expression of perforin in CD8+ T cells (Figure 9B-C). 
Therefore, we may speculate that ICAM-1 and TGFβ2 are utilized by the muscle invasive 
UBC in order to suppress the cytotoxicity of SN CD8+ T cells. One issue to be addressed in 
the future is whether the ICAM-1 signaling is mediated in a contact-dependent or contact-
independent fashion.  
ICAM-1 is known to provide signal 2 upon TCR-dependent T cell activation [198]. When 
ICAM-1 synergistically works with TGFβ2, they both can elicit a potent perforin-deficient 
CD8+ T cell. Furthermore, TGFβ2 has the capability to regulate tumor invasiveness. As 
TGFβ2 was secreted by the muscle invasive UBC, there is a possibility that the TGFβ 
receptor 2 is downregulated by the tumor cells, which will lead to the elevation of 
CXCL1/CXCL5 – CXCR2 chemokine receptor signaling. This will in turn enhance the tumor 
recruitment of MDSCs that can produce MMPs, which supports tumor invasion [145]. Our 
STRING network analysis of the proteomic data supported this notion in which TGFβ2 were 
displayed to interact with CXCL1, CXCL5, and MMP1. 
The limitation of this study relied on the fact that we used an in vitro assay in order to seek 
the causal mechanism behind our ex vivo phenotype. Additionally, due to the limitation in 
isolating viable primary tumor cells form the patient samples, we used UBC cell lines that are 
not entirely representative of the tumor microenvironment. However, we could describe an 
immunosuppressive mechanism that may be used by the muscle invasive UBC tumors to 
dampen CD8+ T cell cytotoxicity.  
Taken together, synergistic ICAM-1 and TGFβ2-mediated pathway may be used as an escape 
mechanism by the muscle invasive UBC tumors to cause perforin suppression in SN CD8+ T 
cells, together with exhaustion and Tc2-skewed environment. This finding may open up a 
possible translational application towards the clinic by targeting ICAM-1 and TGFβ2 in 
combination as a new strategy of cancer immunotherapy. 
 
4.4 NEOADJUVANT CHEMOTHERAPY REINFORCES THE ANTI-TUMOR T 
CELL RESPONSES IN THE SENTINEL NODES (PAPER IV) 
Chemotherapy is one of the standard treatments in solid tumors. The widely known 
mechanism of action of chemotherapy is by direct cytotoxicity towards the tumor cells [199]. 
Surprisingly, evidences have demonstrated that chemotherapy can promote anti-tumor 
immune responses [199, 200]. There are two mechanisms on how chemotherapy induces 
anti-tumor immune responses. First, chemotherapy increases the immunogenicity of the 
tumor cells and second, it reinforces the activation of the immune cells [200, 201]. In this 
study, we focused on the latter mechanism in the human UBC model.  
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In UBC, the standard chemotherapy regimen is to be administered prior to the radical 
cystectomy (neoadjuvant). This regimen consists of Methotrexate, Vinblastine, Adriamycin, 
and Cisplatin (MVAC). Similarly, MVAC is reported to induce the modulation of the 
immune cell responses [202, 203]. In here, we focused on the immunomodulation of T cells 
inside the SNs. SN is the site where APCs present tumor antigens to CD8+ and CD4+ T cells 
[204], resulting in the activation of tumor-specific T cells. Accordingly, SN is an attractive 
site to investigate the T cell immunomodulation by neoadjuvant chemotherapy (NAC). 
In this study, we observed that NAC reduced the exhaustion of CD8+ T cells, marked by a 
lower fraction of CD8+ T cells expressing PD-1 in NAC patients (mean=20%) compared to 
NAC-naïve patients (mean=43.4%). Consequently, the cytotoxic capacity of CD8+ T cells 
increased, as seen by the elevated expression of T-bet, granzyme B, and perforin, in a dose-
dependent manner. Furthermore, this effect was pronounced in patients with complete 
response towards NAC (pT0N0M0 stage) (Figure 10). Additionally, the complete responder 
patients displayed a CpG hypomethylation in the PRF1 and IFNG genes, suggesting that 
CD8+ T cells in these patients are functionally committed cytotoxic cells.  
 
 
 
 
 
 
Similarly, NAC reduced the exhaustion of CD4+ effector T cells, as demonstrated by the 
lower frequency of PD-1+ CD4+ effector T cells in NAC patients (mean=12.2%) compared to 
NAC-naïve patients (mean=24.9%). This resulted in a better clonal expansion of CD4+ 
effector T cells following ex vivo activation using autologous tumor homogenate stimulation. 
Hence, it implies that NAC reduces the exhaustion of the effector T cells in the SNs and 
consequently restores their functions. 
Figure 10. Patients with complete response to NAC have a better CD8+ T cell cytotoxicity. The 
frequency of perforin+ CD8+ T cells from SNs was compared among non responders (≥pT2-N0M0 
stage), partial responders (pTa/pTis/pT1-N0M0 stage), and complete responders (pT0N0M0 stage) of 
NAC. The data from representative UBC patients are displayed in density plots. NAC: neoadjuvant 
chemotherapy, pTNM: pathological tumor-node-metastasis stage, SN: sentinel node, UBC: urinary 
bladder cancer. 
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Surprisingly, Tregs which are known to suppress effector T cells [164], had a lower 
frequency in the SNs of patients receiving NAC, in a dose-dependent manner. In addition, 
SN-Tregs were less activated after NAC treatment, marked by a lower expression of CD39, 
HLA-DR, and PD-1 in these cells.  Moreover, complete responders to NAC had a decreased 
number of Tregs expressing CD39 and CD69. This finding is in line with a previous study on 
breast cancer [205]. Taken together, we find that NAC promotes activation of CD8+ and 
CD4+ effector T cells and reduces the suppressive effects of Tregs. As a consequence, 
patients with complete response to NAC had a higher ratio of CD4+ effector T cell number to 
CD39+ or CD69+ Treg frequency.  
Overall, we observe that patients with a better NAC response have better anti-tumor T cell 
responses. This may be partly explained due to the diversity in the mutational signatures 
among individual tumors, which may affect the susceptibility of each tumor towards the 
cytotoxicity of chemotherapy. Accordingly, in the tumor that is sensitive to the cell-death 
induction by chemotherapy, tumor antigen uptake by APCs i.e. DCs and B cells is enhanced 
[206, 207], resulting in an improved T cell activation in the SNs. Additionally, since the 
histopathological stage of the tumor is downgraded, there will be less chronic inflammatory 
activities in the tumor microenvironment that suppress the T cell functions. Thus, better anti-
tumor CD8+ and CD4+ T cell responses may be incited, alongside the lower recruitment of 
Tregs.  
This study was limited by the fact that the NAC-naïve group that we used as the control was 
not clinically eligible for receiving NAC. Therefore, there was a risk of introducing 
confounding factors when comparing them with patients that clinically were eligible for 
NAC. However, this was the best control that we could obtain, since lymph node resection 
prior to NAC is not possible. Moreover, we could see that the immunomodulatory effects 
exerted by NAC were dose-dependent with significant differences between NAC responders. 
We conclude that NAC reinforces protective anti-tumor T cell responses, which implicates 
that we can optimize the utilization of NAC in the clinic. One possible instance is to use NAC 
in combination with the cancer immunotherapy, such as checkpoint blockade agents [208]. 
The selection of the immunotherapy strategy may be done after the analysis of the T cell 
phenotype following the reinforcement by NAC, as performed in this study. Moreover, future 
clinical application to predict patients that will benefit from NAC treatment by correlating the 
molecular signature subtypes of the tumor to the chemotherapy responses may be needed 
[209]. This will lead to a tailored approach for the patient treatment, since we could see that 
there was a variability of immunomodulation among patients with different NAC responses. 
In other words, we may be able to treat the patients with no response to NAC to have a better 
prognosis in the future.  
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4.5 FLOW CYTOMETRY CAN DETECT MICROMETASTASES IN THE 
SENTINEL NODES OF CANCER PATIENTS (PAPER V) 
One of the outcomes of the immunomodulation by the tumor microenvironment is the tumor 
immune escape acquired during tumor genesis [5]. The impact of such condition is the 
possibility of the tumor cells to progress and metastasize into adjacent lymph nodes or tissues 
and even into distant locations. The presence of metastasis in the lymph nodes itself, has a 
major implication that worsens the prognosis of cancer patients [210, 211]. Hence, a 
sensitive, objective, time- and cost-effective method for detecting metastasis in the lymph 
nodes is critical to be established in light of the increase in cancer incidence. 
In fact, there are several diagnostic methods for detecting metastatic cells in the lymph nodes. 
Microscopic methods to visually examine hematoxylin and eosin (H&E)-stained lymph node 
sections or immunohistochemistry (IHC) are standard histopathological examinations that are 
routinely used in the clinic as a gold standard diagnostic approach in renal cancer [110]. 
However, the weakness of these methods is the possibility to miss micrometastases in the 
lymph nodes since only ~0.1% of the node is sliced into sections, and those sections may not 
contain the metastatic cell deposits [212]. Moreover, these diagnostic procedures are labor-
intensive, subjective, and costly since they are carried out by pathologists.   
Flow cytometry, which is regularly used to phenotype immune cells, offers a practical 
solution due to a possibility of detecting multi parameters of a single cell. Flow cytometry is 
also quick to run and it is an objective method compared to histopathological examination. In 
addition, as we analyzed single-cell suspension derived from the lymph nodes using flow 
cytometry, the chance of missing micrometastases is lower compared to the microscopic 
examination, since all of the metastatic cells are obtained inside the cell suspension [213].  
In this study, we established that cancer cells could be reliably detected using flow cytometry. 
This assay detected three markers of renal cancer cells, which are routinely used for IHC in 
the clinical practice. The markers examined were CA9 and Cad6, both expressed on the cell 
surface, as well as intracellular CK18. Notably, we demonstrated that the intra-assay and 
inter-assay variability were low, which proved the stability of the assay. Furthermore, we 
adopted the International Union against Cancer consensus that defined micrometastasis as a 
tumor deposit between 0.2 to 2 mm [214]. Taking this into account, we assumed that a lymph 
node is ~10 x 5 x 5 mm in size and converted 0.2 to 2 mm of tumor deposit into 0.032% to 
1.6% positive cells out of the total cell number from the lymph nodes.   
Subsequently, we applied our assay to detect metastasis in the lymph nodes from renal cancer 
patients. We demonstrated that four out of five patients initially diagnosed with no metastases 
in their lymph nodes by the histopathological examination, turned out to have metastases 
detected by our flow cytometry method (Table 1). Additionally, six of the metastases-
positive nodes were displayed to be micrometastases (0.032% - 1.6% positive cells) (Table 
1). Thus, it implies that these four patients are restaged from pN0 to pN1, which results in 
different standard clinical treatment and prognosis [114]. One important thing to note is that 
the three markers did not detect the metastatic cells concomitantly. Therefore, it is 
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recommended to detect these markers simultaneously when using this flow cytometry 
method. 
 
Table 1. The results of metastatic cell detection by flow cytometry are compared to the 
histopathological examination in each node from five renal cancer patients.                    
 
 
This study was limited due to a fact that it was performed prospectively, resulting in a short 
follow-up period to obtain the patient clinical information. Therefore, we could not correlate 
the benefit of our metastatic detection method to the patient survival. In the future, it will be 
appealing to do this study longitudinally for a longer period of time, so that it is possible to 
correlate our finding from flow cytometry with relapse free survival, cause-specific survival, 
and overall survival of the patients. 
We conclude that flow cytometry allows detection of a very low number of cancer cells, i.e. 
micrometastases, when present in the lymph nodes. By having a high reliability and stability 
in the metastatic detection, flow cytometry can potentially have a promising future as a 
diagnostic tool. Moreover, we believe that it can be applied to various types of solid tumors 
for a better clinical practice in the future. 
  
CA9: carbonic anhydrase IX, CK18: cytokeratin 18, nSN: non-sentinel node, SN: sentinel node 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Hippocrates once said: “The natural forces within us are the true healers of diseases.” 
Accordingly, over two millennia later, through major discoveries in biology and medicine, 
especially in the field of immunology, this proposed concept is revealed to be partly true. Our 
immune system protects us from infectious diseases and most importantly, from life-
threatening tumors.       
Nonetheless, the nature of the solid tumor microenvironment resembles a labyrinth. Such 
complexity of this microenvironment can modulate the immune cell phenotypes and 
functions in order for the tumors to grow. Correspondingly, the immunomodulation in the 
tumor microenvironment needs to be deciphered, in order to pave the road towards a 
successful cancer immunotherapy. In this thesis, we focus on the modulation of T cells, since 
they are part of the adaptive immune response and they play a central role in tumor immunity. 
Our observations from the TILs in human UBC model indicate the unexpected protective 
function of Tregs in preventing tumor invasiveness. The data suggest that the Tregs residing 
in the invasive front of the tumors suppress MMP2 expression in the tumor 
microenvironment (Figure 11). Consequently, a higher frequency of Tregs in the invasive 
front provides a better survival. However, we still encounter the dual characters of Tregs in 
which they are also suppressive. Overall, Tregs in the UBC tumors express CD39 and CTLA-
4, and they functionally suppress effector T cells. Therefore, prior to designing a cancer 
immunotherapy to target Tregs in UBC, a proper phenotyping of these cells should be taken 
into high consideration. 
Furthermore, the exploration into the effector CD8+ TIL population reveals that TRM cells are 
the most dominant subset in UBC tumors. Tumor TRM cells exhibit an epigenetic 
commitment of cytotoxicity (to transcriptionally express perforin) and they are not terminally 
exhausted, even in the tumor-induced chronic inflammatory microenvironment (Figure 11). 
As a result, their protective roles are seen, in which a lower tumor TRM cell infiltration is 
linked with muscle invasiveness in UBC tumors. Moreover, we discover that the muscle 
invasive UBC tumors may escape immune destruction by suppressing perforin expression in 
CD8+ TEM cells from the SNs via ICAM-1/TGFβ2-mediated signal (Figure 11). Thus, we 
speculate that the muscle invasiveness of the UBC tumors may partly occur due to the faulty 
protection from tumor TRM cells and SN TEM cells. A low frequency of tumor TRM cells 
results in a decreased production of IFNγ which leads to a reduction of chemokines and 
vascular adhesion molecule expression [73]. Consequently, the recruitment and activation of 
DCs and other memory CD8+ T cells will be dampened. The lack of DC recruitment may 
result in a diminished antigenic uptake from the tumors and subsequently may cause a lower 
tumor-specific T cell priming in the SNs [215]. Accordingly, there will be a deficiency of 
new TRM cells and other memory T cells that traffic to the tumor, which may liberate the 
tumors to escape the immune system and grow further, resulting in tumor invasiveness. 
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Nonetheless, it is still an open question regarding which mechanisms that caused the original 
reduction of TRM cell frequency in the muscle invasive tumors. We may argue that the 
mutation and differentiation of tumor cells, including the modification of tumor 
microenvironment over the course of tumor development may make it harder for the TRM 
cells to be retained in the tumor. In addition, it is unknown whether TRM cells are tumor-
antigen specific or that they have already been present in the tissues prior to tumor 
development. In this case, deep sequencing of the recombined TCR genes from the tumor 
TRM cells may provide us a better clue regarding the T cell repertoire [216].  
Furthermore, the promising checkpoint blockade towards CTLA-4, PD-1, and PD-L1 has 
been introduced clinically as cancer treatments. However, not all of the treated patients 
display durable responses [217]. From the studies of the T cell immunomodulation in this 
thesis, we have unveiled several candidates to target for cancer immunotherapy. 
Correspondingly, we may propose to target the Treg suppression and the tumor immune 
escape on CD8+ T cells. In addition, we may expand tumor TRM cells in vitro for an adoptive 
cellular therapy. However, when expanding the tumor TRM cells, initial screening of the cell 
reactivity against the mutations identified by whole-exome sequencing and RNA sequencing 
of the tumors is important. Therefore, the expansion of cells with mutation-reactive TCR 
clonotypes can be secured [218].   
In addition, as we have demonstrated, the use of chemotherapy regimen can promote the anti-
tumor effector T cell responses and reduce the suppressive activity of Tregs (Figure 11). As a 
result, it is reasonable to propose the combination of chemotherapy and immunotherapy for 
more effective therapeutic approaches against cancer and its metastasis [219]. Moreover, 
further studies to investigate the effect of chemotherapy on the cytotoxic TRM cells inside the 
solid tumors can be addressed in the future.   
On the other hand, we still need to remember that the durability of positive clinical responses 
from each cancer immunotherapy is crucial. Thus, in the future era of an unbiased approach, 
it is compelling to broadly characterize the immune cell signatures in the tumor 
microenvironment from each patient prior to deciding the cancer treatment. The immune cells 
from the tumor microenvironment can be evaluated using single-cell RNA sequencing or 
whole genome DNA methylation arrays. Moreover, an approach using CRISPR-Cas9, which 
can identify how genetic manipulation of either T cells or tumor cells can affect the complex 
interplay between them, is an attractive method to be applied [220].   
In summary, the intricacy of the T cell immunomodulation in the solid tumor 
microenvironment needs a thorough exploration. Indeed, the discoveries revealed in the 
tumor-immune interactions have been translationally applied to various groundbreaking 
cancer immunotherapy strategies. But, there are still some drawbacks. Therefore, an 
extensive investigation beyond the current evidences is fundamental to provide a strong 
foundation for cancer immunotherapy, so that we can treat cancer patients optimally. 
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Figure 11. The summary of our findings in this thesis. The major findings from each paper in regards 
of the T cell immunomodulation in the solid tumor microenvironment are illustrated. Paper I 
demonstrates that Tregs regulate tumor invasiveness by suppressing MMP2 in the tumors. Paper II 
reveals that tumor TRM cells are epigenetically cytotoxic and not terminally exhausted. Paper III identifies 
the tumor immune escape mechanism that suppresses perforin in SN CD8+ T cells via an ICAM-
1/TGFβ2-mediated pathway. Paper IV demonstrates that NAC promotes effector T cell functions while 
suppressing Treg activity in SNs. Paper V shows the possibility of detecting micrometastases in SNs by 
flow cytometry. ICAM-1: intercellular adhesion molecule 1, MMP2: matrix metalloproteinase 2, NAC: 
neoadjuvant chemotherapy, SN: sentinel node, TGFβ2: transforming growth factor β2, Treg: regulatory 
T cell, TRM: tissue-resident memory T cells. 
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